°Q½×°Ï>¤ß®®¥ÍÂå
Åý§Ú­Ì¤@°_¬°¤ß®®¥ÍÂå¼g¤é°O
·|­û:²q·Q 10136148 µoªí®É¶¡:2017/8/21 ¤U¤È 05:20:28
§N¼ö´`Àô , ¬O¥|©uªº¥²µM

º¦¶^¥æ´À , ¬OªÑ¥«ªº°¸µM

¶}³o­Óª©¤D¦³·P©ó

Cliff¤j®¦¼w¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡zªº±M·~½×­z

Åý¤p§Ìµo¨¥®É , ²`©È·\¹ï¤j®aªºµ§°O

¤]©È§j½K¤@´ò¬K¤ô , ¯}Ãa¤j®aªY½à±M·~ªº¬ü·P

©Ò¥H , ³o­Óª©

¤£¥u 543 ¥i¥H½Í 1234567890abcdef ¤]Åwªï

§Æ±æ¼ö¾x¬O­ì«h

¥»ª©¬O¦h¨¥°ó ¦h¤è¬Ý¨Æ ¦h±¡¹ï«Ý

¬ß±æ

¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡z¬O§Ú­Ìªº¦@¦Pµ§°O

¡yÅý§Ú­Ì¤@°_¬°¤ß®®¥ÍÂå¼g¤é°O¡z«h¬OÄÝ©ó¤j®aªº¦@¦P¤é°O

´Á«Ý±zªº°Ñ»P

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/22 ¤W¤È 11:43:53²Ä823½g¦^À³
¤Q¦~10»õ¬ü¤¸¤j¦X§@Biogen»PIonis¶i­x¯«¸g¯e¯f

¨Ó·½¡GÃÄ©ú±d¼w¡@2018-04-22

med.sina.com/article_detail_109_2_44643.html

®Ú¾Ú¦X§@±ø´Ú¡ABiogen±N¦VIonis¤ä¥I10»õ¬ü¤¸ªº²{ª÷¡ABiogen¥i¥H¿ï¾ÜÀò±o¦¹¦¸¦X§@²£¥ÍÀøªkªº±ÂÅv³\¥i¡A¨Ã­t³d¨ä¶}µo©M±À¼s¡C¦¹¥~¡ABiogen¥i¯à·|¤ä¥I¨½µ{¸O¥I´Ú¡B³\¥i¶O©M¯S³\Åv¨Ï¥Î¶O¡C

¥¦«Ø¥ß¦b²£¥ÍSPINRAZAªº¦³®Ä¦X§@°ò¦¤§¤W¡ASPINRAZA¬O¯áÅè©Ê¦ÙµäÁY¯g¡]SMA¡^±wªÌªº­º­Ó¤]¬O¥Ø«e°ß¤@Àò§åªºªvÀø¤èªk¡C

°ê½Ã°|¹q¤l³ø712´Á

·sÃĦ^Âk¥¿±`¡Xº©½Í2016¦~FDA®Ö­ã¤p¤À¤l·sÃÄ¡]¤¤¡^

Introduction to FDA approved novel small molecular drugs in 2016 (part 2)

enews.nhri.org.tw/enews_list_new2_more.php?volume_indx=712&showx=showarticle&article_indx=11875

¦³¤¶²Ð(3) Spinraza® (Nusinersen)

2016¦~12¤ë23¤éFDA¶È¥H3­Ó¤ë¼f¬d®É¶¡¡A§Ö³t¦a¥H·sÃħֳt¼f¬d¸ê®æ¡BÀu¥ý¼f¬d¸ê®æ©M©t¨àÃĦa¦ì®Ö­ã¥ÑBiogen»PIonis»sÃĤ½¥q©Ò¦X§@¶}µoªºSpinraza®¡]Nusinersen¡F IONIS-SMNRx¡FISIS-SMNRx¡^¡A¬O²Ä¤@­ÓªvÀøSMAªºÃĪ«¡A§ó¦]¦¹Àò±oFDAµ¹¤©ªºFDA Àu¥ý¼fµû¾ÌÃÒ¡CSpinraza®¤]¬O¤@ºØ¤Ï¸q¹è®Ö苷»Ä¡A¥Î©ó5q¯áÅè©Ê¦ÙµäÁY¯g¡]5q-SMA¡^ªºªvÀø¡A³o¬OSMA³Ì±`¨£ªºÃþ«¬¡A¬ù¥e¥þ³¡SMA¯f¨Òªº95%¡C

FDAªº®Ö­ã¬O°ò©óENDEAR¬ã¨s¦bÀ¦¥®¨à´Áµo¯f«¬SMA¡]infantile-onset SMA¡A³Ì¦³¥i¯àµo®i¬°²Ä1«¬SMA¡^±wªÌªºµ²ªG¡C¦@¦³121¦ì¨ü¸ÕªÌ¡AFDA­n¨D¬ã¨s¹Î¶¤¶i¦æ´Á¤¤¤ÀªR¡]interim analysis¡^¡A¥H¾¨¦­¼f¬d¸ÕÅ礧¦³®Ä©Ê¡Aµ²ªG¦@¦³82¦WSMA±wªÌ²Å¦X´Á¤¤¤ÀªR±ø¥ó¡A¦³40%ªºSpinraza®ªvÀø±wªÌÅã¥Ü¬¡°Ê¤O«ü¼Ð§ïµ½¡A¦Ó¹ï·Ó²Õ¨Ã¥¼Åã¥Ü¦³¥ô¦ó§ïµ½¡C

Spinraza®©ó2011¦~12¤ë19¤é¶i¤J¤HÅéÁ{§É¸ÕÅç¡C2012¦~1¤ë4¤éBiogen¤½¥q©MIsis Pharmaceuticals¤½¥qñ­q¦@¦P¶}µoSpinraza®¦X¬ù¡AIsis Pharmaceuticals¤½¥qÀò±o2,900¸U¬ü¤¸Ã±¬ùª÷¥H¤Î4,500¸U¬ü¤¸¤§¤£¦PÁ{§É¶¥¬q¤§¨½µ{¸Oª÷¡C

·íSpinraza®©ó2015¦~§¹¦¨²Ä¤@­ÓÁ{§ÉII¡þIII´Á¸ÕÅç«á¡ABiogen¦æ¨ÏSpinraza®¤§§ÞÂà¿ï¾ÜÅv¡AIsis Pharmaceuticals¤½¥q¦]¦¹Àò±o2.25»õ¬ü¤¸¡]¥]¬A7,500¸U¬ü¤¸±ÂÅvñ¬ùª÷©M1.5»õ¬ü¤¸ÃÄ«~®Ö­ã¤§¨½µ{¸Oª÷¡^¥H¤Î15%²£«~¤W¥«¤§¾P°âÅv§Qª÷¡F

¦P®É¡ABiogen¤½¥q¤ä¥I©Ò¦³¶}µo¶O¥Î¥H¤Î·íªìIsis Pharmaceuticals¤½¥q¤ä¥Iµ¹§N¬u´ä¹êÅç«Ç©M³Â¦{¤j¾ÇÂå¾Ç°|¤§§ÞÂàªá¶O¡CBiogen¹w©w±NSpinraza®²Ä¤@¦~»ù®æ­q¬°75¸U¬ü¤¸¡AÀH«á¨C¦~ªº¥ÎÃĦ¨¥»¬°37.5¸U¬ü¤¸¡A¥H¬ü°ê¦³1.5¸U¦WSMA±wªÌ¨Ó¬Ý¡A¹w¦ô2025¦~ªº¾P°âÃB¥i¯à·|¹F¨ì17»õ¬ü¤¸¡C

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/19 ¤W¤È 10:29:52²Ä822½g¦^À³
Cancer Association of South Africa (CANSA)

Fact Sheet and Position Statement on Sodium Benzoate and Vitamin C

www.cansa.org.za/files/2017/04/Fact-Sheet-Position-Statement-Sodium-Benzoate-and-Vitamin-C-April-2017.pdf

Sodium Benzoate and Vitamin C in South African Soft Drinks

Every single sample tested negative for benzene. CANSA can, therefore, confirm that all

citrus drinks (those potentially containing Vitamin C) and the preservative Sodium Benzoate

which were tested were found to be safe for consumption.

·íµM CANSA ¤]¦³Ãþ¦ü§K³dªºÁn©ú ½Ð¸Ô°Ñ¸Óºô­¶

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/19 ¤W¤È 09:55:09²Ä821½g¦^À³
³¯¦~ÂÂ¤å ­Ó®×±´°Q

Effect of Long-term Administration of Sodium Benzoate to a Patient with Partial Ornithine Carbamoyl Transferase Deficiency

ªø´Áµ¹¤©­f¥Ò»Ä¶u¹ï³¡¤À³¾®ò»Ä®ò¥Ò酰Âಾ酶¯Ê¥F¯g±wªÌªº¼vÅT

journals.sagepub.com/doi/abs/10.1177/000992288302200309?journalCode=cpja

An 8-year-old girl with partial ornithine carbamoyl transferase deficiency was treated with sodium benzoate (200 mg/kg/day) for 13 months.

¥Î­f¥Ò»Ä¶u¡]200mg / kg /¤Ñ¡^³B²z¨ã¦³³¡¤À³¾®ò»Ä®ò¥Ò酰°òÂಾ酶¯Ê¥F¯gªº8·³¤k«Ä13­Ó¤ë¡C

µ²½×¬O¡Aªø´Á¤fªA­f¥Ò»Ä¶u¥i¦³®Ä­°§C¸Ó±wªÌ°ª®ò¦å¯gµo§@ªºÀW²v©MÄY­«µ{«×¡C

No adverse effect of sodium benzoate were detected by clinical and laboratory examinations.

Á{§É©M¹êÅç«ÇÀˬd¥¼µo²{­f¥Ò»Ä¶uªº¤£¨}¤ÏÀ³¡C

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/18 ¤U¤È 09:14:07²Ä820½g¦^À³
£¸¦ìªA¥ÎNaben±wªÌªº·P¨ü

¸`¦Û

forum.schizophrenia.com/t/sodium-benzoate-my-experience/114454/14

Sodium benzoate - my experience

2018/3/6

A few days into my trial of Sodium Benzoate¡K Having had good results from Glycine, although I couldn¡¦t hack the queezy stomach, I thought I¡¦d see if NaBen was as effective and more easily tolerated. Sarcosine didn¡¦t work for me¡K

2018/4/18(¥b¤p®É«eªº¶K¤å¡^

Well it¡¦s roughly 5 weeks¡K All going well, I seem to be sleeping better, less tired during the day and a bit more motivation. Unlike glycine which made me verge on hypomania, this is much more subtle, which appeals to me. I definitely notice a change for the better and will continue to take it I think.

Whilst physically I feel well, I find myself with nothing to do, where I was content to lie down all day before starting sodium benzoate - I now feel alert and want to do more. I need to change my behaviour to fit my new physical state, old habits die hard¡K I expect that will take some time to achieve though, perhaps CBT would be the answer. At least I feel able to make changes now and hopefully I can follow through and turn things around.

The main thing is that I feel more able to get on with my life, less drained and not so down in the dumps contemplating the point of existance.

ÁÂÁÂLofi¤jªº¤À¨É

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a¡I

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/17 ¤U¤È 07:21:32²Ä819½g¦^À³
¥Í¬¡²ßºD»P°·±d

ĵ±§¡I¨C¶g³Ü°s¶W¹L5ªM¥i¯à·|ÁYµu¹Ø©R

¨Ó·½¡G ¥Íª«±´¯Á ¡@2018-04-17

§@ªÌ¡G³¯²ö¥ì¨Ó·½¡G¥Íª«±´¯Á

med.sina.com/article_detail_103_1_44382.html

¼C¾ô¤j¾Çªº¬ì¾Ç®a­Ì«ü¥X¡A¸g±`¶¼°s¶W¹L­^°ê°sºë«ü«n¡]UK guidelines for alcohol ¡^ªº±ÀÂ˼зǡA¥i¯à·|¨Ï¹Ø©RÁYµu¦n´X¦~¡C¬ã¨sÁÙªí©ú¡A¶¼°s¶V¦h¡A±w¤¤­·¡B­P©R°Ê¯ß½F¡B¤ß¤O°IºÜ©M¦º¤`ªº­·ÀI´N¶V¤j¡C

¨ãÅé¨Ó»¡¡A³o¤@¬ã¨s¤ñ¸û¤F¨Ó¦Û¥þ²y19­Ó°ê®a¶W¹L60¸U¤Hªº°·±d©M¶¼°s²ßºD¡Cµ²ªGÅã¥Ü¡A¶¼°sªº¦w¥þ¤W­­¬°¬ù¨C¶g5ªM°s¡]five drinks per week¡A¬Û·í©ó100§J¯Â°sºë¡^¡C¶¼°s¶q¶W¹L³o¤@¤W­­»P¹w´Á¹Ø©R­°§C¦³Ãö¡CÁ|¨Ò¨Ó»¡¡A¨C¶g³Ü≥10ªM°s»P¹w´Á¹Ø©RÁYµu1-2¦~¦³Ãö¡F¨C¶g³Ü≥18ªM°s»P¹w´Á¹Ø©RÁYµu4-5¦~¦³Ãö¡C

¤[§¤¶Ë¨­¶Ë¤j¸£°ª±j«×Áë·ÒµLªk©è®ø¶Ë®`

¨Ó·½¡G ·sµØºô ¡@2018-04-17

¨Ó·½¡G·sµØªÀ

med.sina.com/article_detail_103_1_44386.html

¬ü°ê¥[§QºÖ¥§¨È¤j¾Ç¬¥§üÁF¤À®Õ¤@­Ó¬ã¨s¤p²Õ¦b·s¤@´Áºôµ¸ª©¾Ç³N¥Zª«¡m¬ì¾Ç¤½¦@¹Ï®ÑÀ]¡Pºî¦X¡n¤W³ø§i»¡¡A¥L­Ì¹ï¤¤¦Ñ¦~¤H¶i¦æªº³o¶µ¬ã¨sÅã¥Ü¡A¤[§¤¤£°Êªº¤H¡A¤j¸£¤¤¤@­Ó¹ï°O¾Ð¦ÜÃö­«­nªº°Ï°ì«p«×·|ÅÜÁ¡¡C§¤ªº®É¶¡¸ûªø»P¤j¸£¤º°¼ù®¸­ÅÜÁ¡¦³ÃöÁp¡C

¤º°¼ù®¸­¬O¤j¸£¤¤°Ñ»P§Î¦¨·s°O¾Ðªº­«­n¸£°Ï¡C¬ã¨s¤H­û»¡¡A¤º°¼ù®¸­ÅÜÁ¡¬O¤¤¦Ñ¦~¤H»{ª¾¯à¤O¤U­°©Mè§bªº«e¥ü¡C

¦¹«e¦h¶µ¬ã¨s¤w¸gµo²{¡A¤[§¤¤£°Ê·|¼W¥[¤H±w¤ßż¯f¡B¿}§¿¯f¬Æ¦Ü¹L¦­¦º¤`ªº­·ÀI¡A¨ä¦M®`³ô¤ñ§l·Ï¡C

¥»¦¸¬ã¨s­t³d¤H´¶©Ô¤Ú¡P§Æ¹F´µ«Øij¡A¬°¤F¨¾½d¤[§¤±a¨Óªº°·±d­·ÀI¡A¤H­Ì­º¥ýÀ³¸Ó´î¤Ö¨C¤Ñ§¤µÛªºÁ`®Éªø¡A¨ä¦¸¦b§¤µÛ¿ì¤½©Î¾Ç²ß®É¡AÀ³¸Ó¹j¤@¬q®É¶¡¯¸°_¨Ó¬¡°Ê¤@¤U¡AÁקK«ùÄò§¤µÛ¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/17 ¤W¤È 08:05:11²Ä818½g¦^À³
¬Q¤Ñ¬Ý¨ì¤@«h°T®§

{{{

¤@ºØ¤ÆÃÄ1Ãþ¶i¤fÃÄ¡GÆQ»Ä¦±°¨¦h-¶ë¨Ó©õ¥¬¦@´¹¤ù

¨Ó·½¡GÃÄ´ç ¡@2018-04-16

§@ªÌ©Ô¤ñ§J

med.sina.com/article_detail_103_2_44342.html

¦@´¹ÃĪ«

¼sªx»{¥iªº¦@´¹ªº©w¸q¬°¡G¥Ñ¨âºØ©Î¦hºØ¤À¤l©M/©ÎÂ÷¤l«¬ªº¤Æ¦Xª«¥H¤@©wªº¤Æ¾Ç­p¶q¤ñºc¦¨ªº§¡¬Û´¹ºA©TÅ骫½è¡A¨Ã¥B¤£¬O·»¾¯¦Xª«©Î³æ¯ÂªºÆQ¡C

³q±`¡A¦@´¹¤¤¦s¦bÃĪ«¬¡©Ê¦¨¤À((Active Pharmaceutical Ingredient ,API)©M¦@§Îª«(Cocrystal former,CCF)¡A¦ý¬O¤]¦s¦bAPI-API«¬ªº¦@´¹¡C

¦@´¹ÃĪ«¨ã¦³¼ç¦b§ïµ½ª«¤Æ©Ê½è¡B¼W¥[·»¸Ñ«×©M¥Íª«§Q¥Î«×µ¥Àu¶Õ¡C

¦³¤@¨ÇÃĪ«³Ìªì¥HÆQªº§Î¦¡¼f§å¤W¥«¡A«á¨Ó³Qµo²{¬O¦@´¹ªº¤è¦¡µ²¦X¡A¦pcafcit®(ÂfÂc»Ä-©@°Ø¦])©MEpilim®(¤þ¥³»Ä-¤þ¥³»Ä¶u)¡C

¦@´¹ÃĪ«§@¬°´¹«¬¬ã¨sªº¤è¦V¤§¤@¡A¨ä¬ã¨s·N¸q¤£¶È¶È¦b©ó´£°ª­ì®ÆÃĪº·»¸Ñ«×¡A§â¦@´¹ÃĪ«§@¬°·s«¬ªºÃĪ«Áp¥Î¤è¦¡¡A§ó¤jµ{«×¦a´£°ªÃĪ«Áp¥Îªº»ù­È¡A±o¨ì1+ 1¡Ö2ªº¦@´¹ÃĪ«¤]³\¥i¥H§@¬°¥t¥~¤@ºØ¬ã¨s«ä¸ô¡C

}}}

³oÅý¤pªº·Q¨ì¤ß®®ªº¦@´¹¤Æ¦Xª«

¨ì©³¥u¬O API + CCF ?

ÁÙ¬O API + API ?

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/13 ¤U¤È 04:14:47²Ä817½g¦^À³
²´¬É ²´¥ú »·¨£

·í¦~¥~¸êª÷µ£½²±R«H¥[¤Jªü¨½¤ë»â2¤d ¦Ñ±C»¡¥LºÆ¤F

2018-04-13 15:51Áp¦X·s»Dºô ºî¦X³ø¾É

udn.com/news/story/7489/3084856

¤@±i¥O¤H¾_Å媺ªüº¸¯ý®üÀq¯f¥¢±Ñ¦a¹Ï

¨Ó·½¡GÂåÃÄÅ]¤è¼Æ¾Ú ¡@2018-04-13

med.sina.com/article_detail_103_2_44230.html

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/13 ¤U¤È 12:57:00²Ä816½g¦^À³
genetinfo.com ³ø¾É

«¢¦ò¾ÇªÌ»{¬°FDA ªº BTD »Ý­n§ï­²

¦ý FDA ¤´°í«ù­ì·N

www.genetinfo.com/investment/featured/item/16004.html

Endpoints News ¬ÛÃö³ø¾É

Does the FDA¡¦s ¡¥breakthrough¡¦ drug program need to be reformed? Harvard skeptics say yes

by john carroll ¡X on April 12, 2018 08:41 AM EDT

Updated: 09:01 AM

endpts.com/does-the-fdas-breakthrough-drug-program-need-to-be-reformed-harvard-skeptics-say-yes/

FDA»Ý­n¤u¨ã¨ÓÃѧO©M¥[³tÃĪ«ªº§å­ã¡A³o¨ÇÃĪ«¥i¥HÅãµÛ§ïµ½±w¦³ÄY­«©Î«Â¯Ù¥Í©Rªº¯e¯f¨Ã¥B¿ï¾Ü¤£¨¬ªº±wªÌªº¥Í©R¡C§Ö³t©M¬ð¯}©ÊÀøªk«ü©w¤w¸g°µ¨ì¤F³o¤@ÂI - ÁöµM¤£¬O¨S¦³¬D¾Ô¡A¦ýªÖ©w¤£·|¼vÅT§Ú­Ì¼f¬dªº¹ý©³©Ê©Î¤ä«ù¼f§åªºÃҾڼзÇ.

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/11 ¤U¤È 08:46:18²Ä815½g¦^À³
§Ü©¬ª÷´Ë·sÃĵo¤O¦û20»õÃĪ«¥«³õ

¨Ó·½¡G ¦Ì¤ººô ¡@§@ªÌ¡G½²¼w¤s¡@2018-04-11

med.sina.com/article_detail_103_1_44133.html

4¤ë11¤é¬O¥@¬É©¬ª÷´Ë¯f¤é¡C¾Ú¬ü°ê°ê¥ß½Ã¥Í¬ã¨s°|(NIH)¼Æ¾Ú¡A¥þ²y½d³ò¤º¤j¬ù¦³400¸U¡ã600¸U©¬ª÷´Ë(PD)±wªÌ¡A¨ä¤¤40%¡ã60%ªº©¬ª÷´Ë±wªÌ¦b¯e¯f§é¿i¤U¡A¦ñ¦³§íÆ{¡B©tÂ}¡Bè§b¡B¦k·Q©M¨gÀêµ¥ºë¯«©Êºî¦X¯g¡A©Ó¨üµÛ´¶³q¤HµLªk·Q¹³ªºµh­W¡AÁÙµ¹®a®x±a¨Ó¨I­«ªººë¯«­t¾á©M¸gÀÙ­t¾á¡C

¾Ú2017¦~¬ü°êIMS¼Æ¾Ú¡A¦b¥þ²y500±jºZ¾PÃĪ«¥«³õ¤¤¡A§Ü©¬ª÷´ËªvÀø¥«³õ¬°20.56»õ¬ü¤¸¡A¦P¤ñ¤W¤@¦~¼Wªø¤F3.73%¡CTOP5ªº«~ºØ¤¤¡Aù´À¤à¥Å(Neupro)¦û¾Ú22.13%¡A¹p¨F¦NÄõ(Azilect)¦û¾Ú21.89%¡A¥ª±Û¥d¤ñ¦h¤Ú(Duodopa)¦û¾Ú17.27%¡A¦h¤Úµ·肼(Madopar)¦û¾Ú16.20%¡A©}©õ¦h¤Ú(Dops)¦û¾Ú11.92%¡A¨ä¥¦3­Ó«~ºØ¦û¾Ú10.59%ªº¥÷ÃB¡C

¾Ú¬ü°êGBI Research°Ó·~±¡³ø¬ã»s¤½¥q³ø§iºÙ¡A¦b·sÃĤW¥«ªº¿EÀy¤U¡A2021¦~¥þ²yPD¥«³õ±N¹F¨ì 32 »õ¬ü¤¸¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/10 ¤U¤È 07:47:26²Ä814½g¦^À³
BACEÃĪ«¬ãµo¨ü®Àªüº¸¯÷®üÀq¯gÀøªk¬ã¨s¨B¨B­²·s

¨Ó·½¡GÃÄ´ç ¡@2018-04-10

§@ªÌ¡G°µÃĪº¤g¨§

med.sina.com/article_detail_103_2_44056.html

¤µ¦~2¤ë¥÷Merck²×¤î¨äBACEÃĪ«verubecestatªº¤T´ÁÁ{§É¬ã¨s¡Averubecestatªº¥¢±Ñ«ê«ê¬°AD¬ã¨s¶}³]¤F¤@ªù¡§·s½Òµ{¡¨¡A±µ¤U¨Óªº¬ã¨s±N´ÂµÛ¦­´Á¤¶¤J©M²Õ¦XÀøªkªº¤è¦Vµo®i¡C

¦Û2013¦~¥H¨ÓFDA­º¦¸¹ïAD«ü«n°µ¥X­×§ï¡A·s«ü«n±N§ïÅÜ»{ª¾§@¬°Á{§É²×ÂI¡A¦Ó¤£¦A¥uÃöª`¥\¯à§ïµ½¡A¥t¥~©ú½Tªº¤@ÂI¬O¤Ï¬M¯e¯f¯f²zªº¥Íª«¼Ð»xª«¡C

¦bAD³õ¤W¡A¦Ñ¶¤­û¤£Â_¥¢±Ñ«o¤£Ä@°h³õ¡A·s¾U¤½¥qÁÙ¦b¤£Â_´é¤J¡C¨s¨ä­ì¦]¡A¥D­n¬O¦]¬°¨ì¥Ø«eÁÙ¨S¦³ÃĪ«¯à°÷ªvÀø©Î©µ½wAD¡A½Ö­n¬O¯à¦³¤@´Ú·sÃĤW¥«¡A­þ©È¥u¬O¯à§ïµ½³¡¤À¯e¯f¶iµ{¡A³£·|¦³¥¨¤jªº¦¬¯q¡C§Ú­Ì¤]¬Ý¨ì¤F«Ü¦h·sªº¹Á¸Õ¡ADenali Therapeutic§Q¥Î·s§Þ³NATVs¨Ó§ó¦nªº±NÃĪ«³z¹L¦å¸£«Ì»Ù¡A¨ú±o¤F¿n·¥®ÄªG¡C¨ä¥L¤½¥q¦p±j¥Í¤½¥qªºJNJ-54861911¡ANovartis©MAmgen¦@¦P¶}µoªºCNP520¡A³£¦b¬ãµo°w¹ï¨ã¦³ADĵ¥Ü°ò¦]APOE4ªº·sÃÄ¡C

½LÂI¡Gªñ20¦~¨º¨Ç¤Æ¾Çµ²ºc¡§¦³·N«ä¡¨ªº42­Ó¤W¥«ÃĪ«(¤W½g)

¨Ó·½¡GÃÄ´ç ¡@2018-04-10

§@ªÌ¡G±j´Ë

med.sina.com/article_detail_103_2_44054.html

¨ä¤¤ ²Ä15ÀÉ ´N¬O Dimethyl Fumarate(´I°¨»Ä¤G¥Òà­)

§Y¦Ê°·¤½¥q¶}µoªº¥Î©óªvÀø¦hµo©Êµw¤Æ¯gªº´I°¨»Ä¤G¥Òà­~Tecfidera¡I

Tecfidera¤@¸g±À¥X¡A«KÀò±o¤F¥«³õªº»{¥i¡C¤W¥«·í¦~¡A¾P°âÃB§Y¦³8.76»õ¬ü¤¸ªº¦n¦¨ÁZ¡A

¦¸¦~(2014)¾P°âÃBªñ©ó30»õ¬ü¤¸¡A¥¼¨Ó´X¦~¤º¡A¸Ó«~ºØªº¥þ²y¾P°âÃB±N¦b40»õ¬ü¤¸¥ª¥k¡C

¥¦¥»¬O¤@ºØ§íµß¨¾¾`ªº¤u·~­ì®Æ¡A«oµØÄRÂਭ¦¨¬°¤H¥ÎÃÄ«~¡F

¥¦³Ìªì»ù®æ§C·G¡A«o³q¹L²Ó¥[Æp¬ã¦Ó¨­»ù¼@¼W¡F

¥¦µ²ºc¹L©ó²³æ¡A«o¯à¦¨ÃĦӥO¤HÅå¹Ä¡F

¥¦¨IÀq¦h¦~¡A¤W¥««á­«½S¬µ¼u®u±²¥þ²y¡C

§íµß¨¾¾`ªº¤u·~­ì®ÆDimethyl Fumarate(´I°¨»Ä¤G¥Òà­) vs. ­¹¥Î¨¾»G¾¯ªºNaBen

¨¬¬°NaBenµo®iªºº]¼Ë

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/9 ¤U¤È 05:55:12²Ä813½g¦^À³
¨ì©³­þ¤@­Ó±µªñ¨Æ¹ê?

Cell¤l¥Z¡G¦Ñ¦~¤H¥i²£¥Í·sªº¸£²Ó­M

¨Ó·½¡G ¥Íª«±´¯Á ¡@§@ªÌ¡G Chen ¡@2018-04-09

med.sina.com/article_detail_103_1_44012.html

1¡B¥ý«eNature¡G¦¨¦~«á¡A¤j¸£®ü°¨Åé·s¯«¸g¤¸´N¡§°±²£¤F¡¨

¸Ó¬ã¨s¥]§t¤F¹ï22¦WÅöíw±wªÌ®ü°¨Å骺¤ÀªR¡C³o¨Ç±wªÌªº¤j¸£³¡¤À³Q¤Á°£¡A¨Ã¥ß§Y³Q³B²z¥Î©ó¤ÀªR¡C¦b³o¨Ç¯f¨Ò¤¤¡A¬ã¨s¤H­û¦b11·³¥H¤Wªº¤H¸s¤¤¨S¦³µo²{¥ô¦ó¦~»´ªº®ü°¨Å鯫¸g¤¸¡C

°ò©ó³o¨Çµo²{¡A§@ªÌ­Ì±o¥Xªºµ²½×¬O¡G·s¥Íªº®ü°¨Å鯫¸g¤¸¼Æ¶q¦b¥X¥Í«á¶}©l´î¤Ö¡A¦¨¦~«á¤U­°¦Ü±µªñ¹s¡C

2¡B³Ì·sCell¤l¥Z¡G¦Ñ¦~¤H¥i²£¥Í·sªº¸£²Ó­M

¸Ó¬ã¨sµ²ªGÅã¥Ü¡A¦Ñ¦~¤H»P¦~»´¤H¨ã¦³¬Û¦üªº¯à¤O¡X¡X¥i±q¯ª²Ó­M²£¥Í¼Æ¥H¤d­pªº®ü°¨Åé·s¯«¸g¤¸¡C¦P®É¡A¤£¦P¦~ÄÖªº¤Hªº®ü°¨Åé¨ã¦³¬Ûµ¥ªºÅé¿n¡C¤£¹L¡A¬Û¤ñ¦~»´¤H¡A¦Ñ¦~¤H¨ã¦³¸û§Cªº¦åºÞ¤Æµ{«×¡A¥B·s¯«¸g¤¸§Î¦¨³s±µªº¯à¤O¸û®z¡C

¾Ú¦¹¡A§@ªÌ­Ì±À´ú¡A¦Ñ¦~®É´Á»{ª¾-±¡ºü¼u©Ê¡]cognitive-emotional resilience¡^ªº­°§C¥i¯à¬O¥Ñ¡§¯«¸g°®²Ó­M¦À¸û¤p¡B¦åºÞ§Î¦¨¯à¤O¤U­°¥H¤Î®ü°¨Å餺²Ó­M¶¡Ãì±µ´î¤Ö¡¨©Ò¾É­Pªº¡C¥¼¨Ó¡A¥L­Ì±N¶i¤@¨B¬ã¨s¦p¦ó³q¹L¿E¯À¡BÂà¿ý¦]¤l©M¨ä¥L²Ó­M¶¡³q¸ô¨Ó½Õ±±¯«¸g²Ó­Mªº¼W´Þ¡B¦¨¼ô©M¥Í¦s¡C

·|­û:´M³V10132258µoªí®É¶¡:2018/4/9 ¤U¤È 02:02:03²Ä812½g¦^À³
www.syneurx.com/press-releases/

2017.05.22 Clozaben®ªvÀøÃøªv«¬ºë¯«¤Àµõ¯g; ¤ß®®¥ÍÂå SND12 IIb/III´Á¦X¨ÖÁ{§É¸ÕÅç­º¤­¦ì¨ü¸ÕªÌ¥¿¦¡¶i¤JÀH¾÷¤À°t¶¥¬q

úE¤ß®®

úë©Ò¦³¤å³¹

¥x¥_¥xÆW 2017.5.22

¤ß®®¥ÍÂ夵¤Ñ«Å¥¬¨ä°w¹ïÃøªv«¬ºë¯«¤Àµõ¯gSND12 IIb/III´Á¦X¨ÖÁ{§É¸ÕÅç¡A­º¤­¦ì¨ü¸ÕªÌ¥¿¦¡¶i¤JÀH¾÷¤À°t¶¥¬q¡C¦¹¶µ¸ÕÅ窺¥Øªº¬OÅçÃҤ߮®¥ÍÂå²£«~½u¨ä¤¤¤@¶µ¥ýÅX©ÊªvÀøClozaben®ªº¦³®Ä©Ê¥H¤Î¦w¥þ©Ê¡A¨ü¸Õ¹ï¶H¬OÃøªv«¬ºë¯«¤Àµõ¯g¦¨¤H¯f±w¡C

Clozaben®¬O¤@ ­Ó¥þ·sªvÀø¾÷Âà ¡V §í¨îD-Ói°ò»Ä®ñ¤Æ酶 (D-amino acid oxidase) ¡V ¦X¨Ö´â´á¥­ (Clozapine) ªº²Ä¤@­Ó·sÃÄ¡C´â´á¥­¬OÃøªv«¬ºë¯«¤Àµõ¯f±wªº°ß¤@©M³Ì«á¤@½u¥ÎÃÄ¡C¦ô­p¦³30%©Î§ó°ª¤ñ¨Òªººë¯«¤Àµõ¯g¯f±wÄÝ©óÃøªv«¬ªº±Ú¸s¡C¥Ø«eÃøªv«¬ºë¯«¤Àµõ¯g¥ÎÃĪº­·ÀI°ª¥BÀø®Ä¤£¹ü¡A«æ»Ý¶}µoÀu½èªºªvÀø¨Ó¹w¨¾©Î´î½wºë¯«¯f¯gª¬¡B¥\¯à¯Ê¥¢¡B¥H¤ÎÄY­«ªºÃĪ«°Æ§@¥Î¡C

SND12Á{§É¸ÕÅç¹w­p¦b¬ü°ê¡B¥[®³¤j¡B¥H¤Î¼Ú¬w¤£¶W¹L40­Ó¤¤¤ß¦¬®×¬ù287¦ì¨ü¸ÕªÌ¡A¶i¦æ¬°´Á8©PªºÂùª¼¸ÕÅç¡CClozaben®ªø´ÁªvÀøªº¦w¥þ©Ê±N¥Ñ³Ìªñ±Ò°Êªº SND13¸ÕÅ礤¡A52©Pªº¶}©ñ©µªø¸ÕÅç¨Ó¤ä«ù¡C

SND12Á{§É¸ÕÅç±o¨ì¬ü°êFDA±Â»P©t¨àÃÄ¡]ODD¡^¥H¤Î¬ð¯}©ÊªvÀø¡]BTD¡^Âù­«»{©w¡C©t¨àÃÄ»{©w±N«OÅ@¦¹·sÃĦb¥«³õ¤W 7¦~ªº¿W®a±M½æ´Á¡C¬ð¯}©ÊªvÀø»{©w¦b¤¤¼Ï¯«¸g¯e¯f»â°ì«D±`¨u¨£¡C¦¹¬ð¯}©ÊªvÀø»{©wÃøªv«¬ºë¯«¤Àµõ¯g¬O¤@ºØÄY­«ªº¯e¯f¡A¥B¥Ø«e¦³®ÄªºªvÀø«D±`¦³­­¡C³o¶µ¬ð¯}©ÊªvÀø»{©wªÖ©wClozaben®¦bªì´ÁÁ{§É¸ÕÅçµ²ªGÅã¥Ü¨äÃĮĤj´TÀu©ó²{¦³ªºªvÀø¤èªk¡C

¥Ñ©ó¦³¬ð¯}©ÊªvÀø¡]BTD¡^¥H¤Î©t¨àÃÄ¡]ODD¡^ªºÂù­«»{©w¡A ¬ü°êFDA±N©ó¸ÓÃĸÕÅç¤Î®Ö¼fªº¹Lµ{·í¤¤¡A ´£¨Ñ§ó¦hªº¤ä«ù»P»²¾É¡A¥H³Ì§Ö³Ì¦³®Ä²vªº¾úµ{§¹¦¨·sÃĶ}µo¡C

¤ß®®¥ÍÂå°õ¦æªø­Ý¸³¨Æªø½²ªG¯þ±Ð±Â»¡¡G¡uÃøªv«¬ºë¯«¤Àµõ¯g´N¹³¬O¥½´ÁÀù¯g¨S¦³¦nªºªvÀø¤èªk¡A¥Ø«eÃøªv«¬ºë¯«¤Àµõ¯gªºÃĪ«ÃĮīD±`¦³­­¡A´â´á¥­¬O°ß¤@ªº¿ï¾Ü¡C Clozaben®¬O¥H¯f¤H¬°¥»ªº¤@¶µ·s¿oªvÀø¤è¦¡¡A¥Øªº´N¬O­n°w¹ï³o­Ó«æ»Ý³QÃöª`ªºÃøªv«¬ºë¯«¤Àµõ¯g±Ú¸s¡AÂǥѧﵽ¯f±wªº¤Ûı¸ò¦k·Qµ¥¥¿©Ê¯gª¬¡B¤Î´£¤É¨ä©Ò»ÝªºªÀ·|¯à¤O¥H¤Î»{ª¾¯à¤O¡A¥H§ïµ½¥L­Ì¤é±`¤u§@©Î©~®aªº¥Í¬¡¥\¯à¡C¦pªG¦¨¥\¶}µo¥X¨Ó¡A±N¨³³t¦¨¬°Ãøªv«¬ºë¯«¤Àµõ¯gªº­º­nÂåÀø¿ï¶µ¡C¡v

Ãö©ó SND12Á{§É¸ÕÅç

·Q­n§ó¦h¤F¸Ñ SND12 ªºÁ{§É¸ÕÅç¥H¤Î¦¬®×¸ê°T¡A½ÐÂI¿ï¦¹syneurxtrials.com/Trials/Refractory-Schizophrenia³sµ²¡C

Ãö©ó¤ß®®¥ÍÂåªÑ¥÷¦³­­¤½¥q

¤ß®®¡]6575¡^¬O¤@®a¦C©ó¥xÆW¿³Âdªº¥þ²y©Ê¥Íª«¬ì§Þ¤½¥q¡A¸Ó¤½¥q±M¬ã©ó¤¤¼Ï¯«¸g¯e¯fªº·sÃĬãµo¡C¤½¥q±Mªø©ó¤¤¼Ï¯«¸g¯f¯gªº·sÃĬãµo¡A¥Ø«e¥¿¦b¶i¦æ¼Æ­Ó±ß´ÁÁ{§É¸ÕÅç¡A¤]¦³¼Æ­Ó¬ã¨s±µªñ±ß´ÁÁ{§É¶¥¬q¡A¨ä¾AÀ³¯g¥]¬A­«¤j¤¤¼Ï¯«¸g¯f¯g¦pºë¯«¤Àµõ¯g¡B¥¢´¼¯g¥H¤Î¼~Æ{¯gµ¥¡C

§K³dÁn©ú¡G

¥»·s»D½Z¨Ã¤£ºc¦¨§ë¸ê©ÎÁʶR¤ß®®¡]6575¡^ªÑ²¼¤§ÁܽЩέn¬ù¡C¤×¨ä¡A¹ê»Úµ²ªG¤Î¥¼¨Óµo®i¥i¯à»P¥»·s»D½Z¤§¥ô¦ó·N¨£©Î´Á±æ¦³­«¤j®t²§¡AÃÒ¨é»ù®æ¹L¥hªºªí²{¤£¯à§@¬°¨ä¥¼¨ÓÁZ®Äªº«ü¼Ð¡C·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

©Î³\¦³ªÅ¥i¥H¥h¤½¥qºô¯¸³}³}~~·|¦³¤£¦Pªº«ä¦Ò!!

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/9 ¤W¤È 08:22:47²Ä811½g¦^À³
genetinfo.com

¦C¥X---¼vÅT¼Æ¦Ê¸U±wªÌ¤H¥Íªº 12 ¤j°I®z¯e¯f

www.genetinfo.com/investment/featured/item/8437.html?limitstart=0

¥]¬A :

1. ªü¯÷®üÀq¯g»P¥¢´¼¯g

2. ¦Ù¦×µäÁY©Ê¯áÅè°¼¯Áµw¤Æ¯g

3. ©¬ª÷´Ë¤ó¯g

4. ¦hµo©Êµw¤Æ¯g

5. µw¥Ö¯g

6. Ån©ÊÅÖºû¤Æ¯g

7. ºC©Êªý¶ë©ÊªÍ¯e¯f

8. ¸£©Ê³Â·ô

9. ¦Ù¦×µäÁY¯g

10 ¯áÅè¦Ç½è¯g(¤p¨à³Â·ô)

11 «äı¥¢½Õ¯g

12 Ãþ­·ÀãÃö¸`ª¢

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/6 ¤W¤È 10:13:41²Ä810½g¦^À³
¤å¦@½à

ºK¦Û¦Ñ¥v¤j¤j´¿´£¤Îªº¤å³¹

www.ncbi.nlm.nih.gov/pmc/articles/PMC5265239/

Analysts have identified five unmet needs in the schizophrenia marketplace. They include:

Drugs that enhance cognition

Drugs that treat negative symptoms (such as lethargy, apathy, and social withdrawal)

Drugs that provide improved options for treatment-resistant patients

Drugs with enhanced safety profiles

Drugs that increase compliance

ºë¯«¤Àµõ¯g¥«³õ¤¤¤­­Ó¥¼º¡¨¬ªº»Ý¨D¡C¥]¬A¡G

¼W±j»{ª¾ªºÃĪ«

ªvÀø³±©Ê¯gª¬ªºÃĪ«¡]¦p¶ÝºÎ¡A§Nºz©MªÀ¥æ°hÁY¡^

´£¨Ñ§ïµ½­@ÃıwªÌ¿ï¾ÜªºÃĪ«

¼W¶i¦w¥þ©ÊªºÃĪ«

¼W¥[¨Ì±q©ÊªºÃĪ«

NaBen ²[»\¤F´X­Ó©O?!

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/5 ¤U¤È 10:11:35²Ä809½g¦^À³
°£¤FÃøªv«¬«äı¥¢½Õ¯g¥~¡A

¹ï©ó¨ä¥L¾AÀ³¯g

Clozapine + NaBen ¬O§_®ÄªG¤]·|§ó¦n¡H¡H¡H

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/5 ¤U¤È 10:02:39²Ä808½g¦^À³
Clozapine Underutilization: Addressing the Barriers

National Association of State Mental Health Program Directors

66 Canal Center Plaza, Suite 302, Alexandria, VA 22314 703-739-9333 FAX: 703-548-9517

nasmhpd.org/sites/default/files/Assessment%201_Clozapine%20Underutilization.pdf

Clozapine¡¦s Efficacy

Clozapine is the most effective antipsychotic for patients with schizophrenia who do not respond to treatment with first- or second-generation antipsychotics. [1] Several meta- analyses of controlled trials and systematic reviews of clozapine provide evidence of its superiority. [2-7] The most recent meta-analysis[8] reported that clozapine (effect size relative to placebo= 0.88) was almost twice as efficacious as other available antipsychotics.

Broader Range Effectiveness of Clozapine

Clozapine is recognized as superior to other antipsychotics in several treatment guidelines and recommendations for treatment resistant schizophrenia. The Schizophrenia Patient Outcomes Research Team (PORT)[12] summarizes the large evidence-based literature supporting clozapine as the gold standard and recommends that patients with persistent positive symptoms of schizophrenia receive an adequate trial of clozapine

In addition to schizophrenia and schizoaffective disorder, accumulating evidence supports clozapine¡¦s utility for a variety of other disorders and conditions, such as the treatment of hostility and aggression,[17] treatment-resistant bipolar disorder,[18] psychogenic polydipsia/hyponatremia,[19] Parkinson¡¦s disease psychosis[20] and psychosis in Lewy body dementia,[21] borderline personality disorder[22], and tardive dyskinesia (TD).[23] Growing evidence also suggests clozapine may be an option in youth with early onset schizophrenia.[24] Importantly, clozapine is the only antipsychotic with a Food and Drug Administration approval for suicidality.

Underuse of Clozapine

Overcoming Barriers to Clozapine Use

.........

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/5 ¤U¤È 01:02:47²Ä807½g¦^À³
»D¦@½à

§Üºë¯«¯fÃĪ«¦ÑÃÄ---´â´á¥­ ©ÎªF¤s¦A°_

www.jkcyjy.com/show-41-442-1.html

­^°ê¶i¦æªº§Ü«äı¥¢½Õ¦ÑÃĪº¬ã¨s ¥i¯à¹ï´â´á¥­ªº°Æ§@¥Î°ÝÃD¥­¤Ï

´â´á¥­¬Û¹ï¨ä¥LÃĪ« ¦º¤`²v§C¤F¤£¤Ö

³o¥÷³ø§i¤w¤Þ°_FDA©M¼Ú¬wÂå¬Éªº°ª«×­«µø ¥i¥H¬Û«H ¥¼¨Ó¾P°âÁÙ±NÄ~Äò¤W¤É

¥Ø«e´â´á¥­¥þ²yÁ`¾P°âÃB¦ô¦b 7 ~ 9 »õ¬ü¤¸

ªñ´Á¦hµo©Êµw¤Æ¯gÀøªk¶i®i¤@Äý

¨Ó·½¡G ¥Íª«¨¦ ¡@2017-09-21

med.sina.com/article_detail_103_1_33939.html

´fÆF¹yºû¦h§Q¨È¤j¾Ç¬ã¨s¤H­ûµo²{¡G¨Ï¥Î±`¨£ªº§Üºë¯«¯f¾¯¡A©Î³\¥i¥HªvÀø¦hµo©Êµw¤Æ¯g¡]MS¡^¡C

¬ã¨s¤H­ûAnne La Flamme³Õ¤h»â¾Éªº·s¬ã¨s¡AÅã¥Ü´â´á¥­©M§Q°öଦ³¼ç¤O¦¨¬°¦³®ÄªvÀøMSªºÃĪ«¡C

§Üºë¯«¯fÃÄÀø®Ä¶V¨Ó¶V¤£µ¹¤O¡H

2017-06-09

med.sina.com/article_detail_103_2_27255.html

³o¹ïClozaBen¦b¥¼¨Ó­Y¦¨¥\¤W¥«ªº¾P°â¦³§U¯q¶Ü?!

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:³¯ÀR10141886µoªí®É¶¡:2018/4/4 ¤W¤È 08:45:41²Ä806½g¦^À³
ALKS ¥Î¾~¤ùÃþªºßÓªv¤×Æ{¯g¡B©MJJ¥Îketamine ¤@様³£¬O°­¥´Àð¡C¥i¤F¸Ñ³o»â°ì¦hÃø¡B¤jÃļt¤]§ô¤âµLµ¦
·|­û:²q·Q10136148µoªí®É¶¡:2018/4/3 ¤U¤È 04:02:11²Ä805½g¦^À³
¦A¬Ý¤@¦¸ALKS 5461 ªº³ø¾É

°Ó·~­p¹º¥´¶Ã­«½S§Æ±æªw´ö¡IAlkermes§íÆ{¯g·sÃľDFDA©Úµ´

¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-04-03

med.sina.com/article_detail_103_2_43776.html

Alkermes¬O¤@®a±Mª`©ó¶}µo³Ð·sÃĪ«¥Î©óªvÀø¤¤¼Ï¯«¸g¨t²Î¡]CNS ¡^¯e¯fªº·Rº¸Äõ»sÃĤ½¥q¡Cªñ¤é¡A¸Ó¤½¥qªí¥Ü¡A¨ä¹êÅç©ÊÃĪ« ALKS5461ªº·sÃĥӽС]NDA¡^¦¬¨ì¤F¨Ó¦Û¬ü°ê­¹«~©MÃĪ«ºÞ²z§½¡]FDA¡^ªº©Úµ´¨ü²z³qª¾®Ñ¡]refusal-to-file letter¡^¡C¨ü¦¹®ø®§¼vÅT¡AAlkermes¤½¥qªÑ»ù¦b½L«e¥æ©ö¤¤¤U®À20%¡CÁ`¥«­È³Ñ 70 »õ¬üª÷.

ALKS5461¥Ñ©T©w¾¯¶qªº¤B¤þ¿Õ°Ø©Msamidorphan¡]ALKS-33¡^²Õ¦¨¡A¨ä¤¤¤B¤þ¿Õ°Ø¬O¤@ºØ£g-ªü¤ù¨üÅ鳡¤À¿E°Ê¾¯©M¥\¯à©Êk-ªü¤ù¨üÅé«ú§Ü¾¯¡A¨ã¦³¦¨Å}­·ÀI¡Fsamidorphan«h¬O¤@ºØ·s«¬ªº¿ï¾Ü©Ê±j®Ä£g-ªü¤ù¨üÅé«ú§Ü¾¯¡A¥i¥H©è®ø¤B¤þ¿Õ°Øªº¿E°Ê¾¯¥\¯à¡A¨Ï¨ä¥u³Ñ¤Uk-ªü¤ù¨üÅé«ú§Ü¾¯¥\¯à¡C±N³o2ºØÃĪ«¶i¦æ²Õ¦X¡A¦®¦b³Ð³y¤@ºØ·sªº¥\¯à©Êk-ªü¤ù¨üÅé«ú§Ü¾¯¡C

Jefferies¤ÀªR®v«ü¥X¡A¦­¤w¹w®Æ¨ì¤F³o­Ó´I¦³ª§Ä³ªº¨M©w¡A¦]¬°Alkermes¤½¥q¶}®i¤F3­ÓIII´Á¬ã¨s¡A¨ä¤¤2­Ó¥¢±Ñ¡A¥t1­ÓÀò±o¦¨¥\¡C¦Ó¸Ó¤½¥q´N¬O¨Ì¾Ú³o­Ó¦¨¥\ªºIII´ÁÁ{§É¼Æ¾Ú´£¥æ¤FNDA¡A¦ý¬O¸Ó¶µ¬ã¨s±Ä¥Î¤F®É¶¡¥[Åvªº¥­§¡²×ÂI¡A³o¹ï©ó§íÆ{¯gÁ{§É¬ã¨s¦Ó¨¥ÁÙ¬O­º¦¸¡C¦]¦¹¥i¥H¹w®Æ¨ì¡AFDA¥i¯à»Ý­n´£¨ÑÃB¥~ªºÁ{§É¬ã¨s¼Æ¾Ú¡C

°£¤FALKD5461¤§¥~¡AAlkermes¤½¥q¤w¦VFDA´£¥æNDA¥Ó½ÐªºÁÙ¦³¤@­ÓÃĪ«¡A´N¬OALNCD¡]ªü¥ß哌Ðü-lauroxil¯Ç¦Ì´¹Åé¤À´²¾¯¡^¡A³o¬O¸Ó¤½¥q¤w¤W¥«²£«~ºë¯«¤Àµõ¯gÃĪ«Aristada¡]ªü¥ß哌Ðü-lauroxil¡^ªº·s¾¯«¬¡AFDA¤w«ü©wPDUFA¥Ø¼Ð¤é´Á¬°2018¦~6¤ë30¤é¡C

¦¹¥~¡AAlkermes¤½¥qºÞ½u¤¤ÁÙ¦³2­Ó¸ê²£³B©óIII´ÁÁ{§É¶}µo¡A¥]¬Aºë¯«¤Àµõ¯gÃĪ«ALKS3831©M¦hµo©Êµw¤Æ¯gÃĪ«BIIB098 (¤w±ÂÅvµ¹¦Ê°·¡^¡C¡]·s®öÂåÃĽsĶ/newborn¡^

·|­û:¤p·ç10140606µoªí®É¶¡:2018/4/3 ¤U¤È 03:48:43²Ä804½g¦^À³
ªñ´Á¸êª÷´é¤J¥Í§Þ¡A¬O¦]¬°¥«³õ¤W¥i¥Hª£§@ªº¼Ðªº³£¤w¸g³Qª£Â½¤F¡A

¥Í§Þªº°ò´Á¸û§C¡A¦]¦¹¦¨¬°¤º¸ê¥D¤Oª£§@ªº¼Ðªº¡A

¦ý¥xªÑ«D±`¯«©_¡A³s°µ¤Æ§©«~ªº¤]¥i¥HºÙ¬°¥Í§Þ¡AXX¤¤¤ßÁÙ¿³°ªªö¯P¦a§ä³o¨Ç¤Æ§©«~¤½¥q¿ì·~ÁZµoªí·|¡A

¤p§Ì¨S¦³ª[µø³o¨Ç¤Æ§©«~¤½¥q¡A

¦ý¯u¥¿¦³Ãzµo¤O¡B¦³µo®i¼ç¤Oªº¤½¥q¡AXX¤¤¤ß«o³£¤£´±ÁܽСA

¹ï¤ñ¹L¥h¯E­ôÁÙ¨S¸Ñª¼®É¡AXX¤¤¤ßÁÙ·|§ä¯E­ô¿ì·~ÁZµoªí·|¡A¯u¬O«D±`·|ÀA¤W²Kªá°Ú~~

¤µ©õ¬Û¤ñ¡A¥O¤H¤£³Ó®D¼N~

¦ý¸ô»»ª¾°¨¤O¡A¤é¤[¨£¤H¤ß¡A

µ¥®ö¼é°h¥h´N¥i¥H¬Ý¨£½Ö¦b»rªa~

·|­û:¤p·ç10140606µoªí®É¶¡:2018/4/3 ¤U¤È 03:32:41²Ä803½g¦^À³
¤p©¯¹B¤j±z¦n,

§Ú«Ü»{¦P±z¹ï¥Í§Þ·sÃIJ£·~ªº«H¤ß¡A

¦ý§Ú­Ì¹ï¤½¥qªº«H¤ß¬O¨Ó¦Û¤½¥q¥D¨ÆªÌªº§V¤O©M§ë¤J¡A

¦ýµ´¹ï©M ¶i¤á ¨S¦³¥ô¦óÃöÁp¡A

¶i¤á ¥u¬O³Û³Û¤f¸¹¡A

¦pªG»{¯uÀËÅç¥L­Ì³ÛªºªF¦è©M¹ê»Ú¦¨ªG¡A¨ä¹ê³£¥u¬O¨Ç§@¤å¡A

¤f´f¦Ó¤£¹ê¡A¤p§Ì¬O¸ê²`¯E­ô§ë¸ê¤H¡A

¬Ý¨ì¯E­ô³Q¼Æ¦r©P¥Z³sÄò¦n´X´Á¥ÎÀYª©¦ø­Ô¡A

¶i¤á ¤£»D¤£°Ý¡A

¹ï¬ü°êªÑ¥«ªk³Wµy¦³¤F¸ÑªºªO¤Í¤@©w¥i¥Hª¾¹D³o°¨¤W·|³Q½Õ¬d¡A

¦]¬°¤£¹ê³ø¾É¼vÅTªÑ»ù¦b¬ü°ê¬O«ÜÄY­«¡A

¦ý¦b¥xÆW¡A§Ú­Ì¥u¬Ý¨ì ¶i¤á ³·¤¤°e¦B¡A

§Ú­Ì¹ïªÑ»ùªº«H¤ß¬O°ò©ó¹ï¤½¥q¥D¨ÆªÌªº«H¿à¡A

«Øij±z¤£­n¦A´£ ¶i¤á ¬Fµ¦¤F¡A¨º¨ÇªF¦è¹ï¤½¥q§¹¥þ¨S¦³À°§Uªº~~

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/4/3 ¤U¤È 01:17:20²Ä802½g¦^À³
³¯ÀR¤j...

§Ú¥u¯à»¡...«Ü¦h¨Æ±¡¤£¬Oªí­±¤W¬Ý¨ìªº³o¼Ë...

§Ú­Ì¥u¬Ýªº¨ìÂi­±¤W½æ...¬Ý¤£¨£Âi­±¤U½Ö¶R¨«¤F...

------------------------------------------------------------------

¥Í§Þ¾ã­Ó±Ú¸s¤@¸ô¶^¤F¨â¦~¦h...¥D¦]¤£¬O°·¨È¥´À£³y¦¨ªº...§O¦A¬Ý¥H«eªº·Î¼õ¤é¤l...

­n¦³«H¤ß¬Ý¦V¥¼¨Ó...²{¦b¥xÆW¬F©²¬Fµ¦´N¬O¿n·¥§@¦h§ß´Ó¥Í§Þ²£·~...

¸êª÷¤]³°Äò´é¤J¥Í§Þ¦U¤½¥q..¤µ¤é¤j½L¶^¤Fªñ¦ÊÂI..¦ý¥Í§Þ«ü¼Æºû«ù¥­½L¤W¤U..

¥Í§Þ¤µ¦~ªº¥D¬yÁͶշ|¤@¸ô©µÄò¤U¥h...

-------------------------------------------------------------------------

ªñ´Á¤¤°ê´f¥x¬Fµ¦¤U..¤ß®®²Å¦X­u´äªº¸ê®æ...

¤£½×¤½¥q«áÄò¥h¤£¥h´äªÑ±¾µP...¦Ü¤Ö¸ê®æ¬O¦³¤F...

¯à®³¨â±i¬ü°ê»{ÃÒªºBTD..¦³¨¬°÷ªº°ê»Ú»ù­È¤Î¬G¨Æ©Ê...

¬Û«H¤½¥qªº¬ãµo¹ê¤O...¤â¤W±M§Qªº»ù­È...

«áÄò¥«³õ¸êª÷¼é¦Á³°Äò´é¤J¤U...ªø½u§ë¸êªÌ¥²©w·|¦³§ó¦h¤H¿ï¾Ü¤ß®®¶i¦æ§ë¸ê...

---------------------------------------------------------------------------

¥H¤W­Ó¤HÁ¡¨£.....¨Ñµ½¨}.´¼¼z.ªø´Á§ë¸êªº¤j¤j­Ì°Ñ¦Ò......

·|­û:³¯ÀR10141886µoªí®É¶¡:2018/4/3 ¤W¤È 11:23:16²Ä801½g¦^À³
¤£¯à­e¦P¡B³oºØ¨â­±¤âªkªº¤X¤½¥q´NÀ³·í¦b¶§¥ú¤UÀËÅç¡C¦pªG§A»¡ªº対¡B¤ß®®¬O°ê»Ú¯Åªº¦n¤½¥q¡B¥´压¤ß悦¡B¤£´Nµ¥©ó¬O¥´圧¥xÆWªº¥Í§Þ¶Ü¡H¯à鄕º@¶Ü¡HY¤½¥q¸Ó·í¦ó¸o¡H
·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/4/3 ¤W¤È 10:46:56²Ä800½g¦^À³
³¯ÀR¤j~~

ª©¤Wªø´Á§ë¸ê¤ß®®ªº¤j¤j­Ì¤j³£¹ï°·¨Èªº½æªÑ«Ü¤£²n...

¦ý¤W¥«Âd¤½¥q´N¬O³o¼Ë...¤½¥q¬°¤FEPS¬°¤F°]³ø¦n¬Ý·QºÉ¿ìªk...

¬Ý¬Ýªñ´Áªº°·¨È±q2¤ë§CÂI28.2¤¸º¦¨ì¤µ¤é¥Ø«e40¤¸¥H¤W...

¦ý.Âi­±¤W½æªÑ²¼.Âi­±¤U½Ö¥þ³¡±µ¨«..½Öª¾¹D?

ªÑ»ù·|¤Wº¦¥²©w¦³¨ä­ì¦]...

¤ß®®ªºCNS¬ãµo¯à¤O¦b°ê»Ú¤W¬O«e¬q¯Zªº¦n¤½¥q...

§O¦A¥h§è°·¨È½æ¤£½æªÑ...¨º¤w¸g¬O1¦~¦h«eªº¦Ñ¸ÜÃD...

µ¥¤§«á¤ß®®¬ãµo¶i«×¦¨ªG³°Äò¦³¦n¼Æ¾Ú§e²{®É...

¦ÛµM·|ÁÙµ¹ªø´Á§ë¸êªº¤¤¹ê¤á©M¤j¤á­ÌÀ³¦³ªº¦¬Ã¬...

¥H¤W­Ó¤HÁ¡¨£~~¶È¨Ñµ½¨}.´¼¼z.ªø´Á§ë¸êªº¤j¤j­Ì°Ñ¦Ò

·|­û:³¯ÀR10141886µoªí®É¶¡:2018/4/3 ¤W¤È 10:19:20²Ä799½g¦^À³
¨ä¹ê¸Ó¥h­»´ä¤W¥«ªº¬O°·¨È¡B¤â¤W³£¬O¶r²¼¡B¥Í·N°µ¤£¦n´N½æªÑ¡AÀ禬Àò§Q¤£·|Áà
·|­û:²q·Q10136148µoªí®É¶¡:2018/4/3 ¤W¤È 10:13:07²Ä798½g¦^À³

Alkermes Receives Refusal Letter From FDA On NDA Filing For ALKS 5461

April 02, 2018, 07:23:00 AM EDT By RTT News

www.nasdaq.com/article/alkermes-receives-refusal-letter-from-fda-on-nda-filing-for-alks-5461-20180402-00199

·|­û:´M³V10132258µoªí®É¶¡:2018/4/3 ¤W¤È 09:41:34²Ä797½g¦^À³
¨S´£¼W¸ê~¥i¯à¬O¤½¥qµû¦ô¥Ø«e¸êª÷°÷§¹¤â¤W¶i¦æªº®×¤l~

·íµM²{ª÷¶V¦h¶V¦n!

«Ü¦h¨Æ±¡¤½¥qÀn¤l·Æ¤ô¨ì²{¦b³°Äò¦³ÂI¦¨ªG¤F~

§O§Ñ¤F¤â¤WÁÙ¦³ªº±M§Q´N°÷À~¤Hªº!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/4/3 ¤W¤È 09:38:21²Ä796½g¦^À³
©ñ¤ß§a~~°·¨È¥ý«e´N½æ¤£¤U¥h¤F...·|¦³¤H§âÄw½X±µ¨«ªº...

4/2³ø¾É´£¨ì¤U¤å...­Ó¤H»{¬°´N¬Oª½«ü¤ß®®...°ê»Ú¬G¨Æ>>2±iBTD¦b°ê»Ú¤W°÷¤À¶q¤F...

------------------------------------------------------------------------------------

µØ«Â³Ð§ë¦X¹Ù¤H§õ¥@¤¯ªí¥Ü¡A´ä¥æ©Ò­º³Ð³Ð·~ª©ªºIPO³W¹º¡A

¬O¤ñ·Ó¬ü°ê¼Ð·Ç¡A¥Ñ«ß®v¨Æ°È©Ò°e¥ó¡A¨é°Ó¶i¦æ©Ó¾P¡F¬°¤F¬ðÅã®æ§½¡A

IPO¤½¥q¥²¶·­n¦³¨ã°ê»Ú±M·~­I´ºªº¥~³¡ªÑªF¡A¦pªG¡u°ê»Ú¬G¨Æ¡v³sµ²¤£±j¡A®£Ãø²æ¿o¦Ó¥X¡C

----------------------------------------------------------------------------------------

·|­û:³¯ÀR10141886µoªí®É¶¡:2018/4/3 ¤W¤È 09:24:10²Ä795½g¦^À³
¤@´[±¡Ä@¨S¥Î¡A¥Íµ¦会対´ä¥æ©Ò¨S¦³¸m°Öªº¾l¦a¡C¥xÆWªº¥Í§Þ¡BÀô¹ÒÀI´c¡Cµ¥°·亜¨â­±¤âªk¡B¦A½æ¥|¤d±iÀ±¸ÉÁ«·l¡A¤£¬O¦A³Q¥´­w¤F www.chinatimes.com/newspapers/20180403000367-260206
·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/4/3 ¤W¤È 08:20:19²Ä794½g¦^À³
¤¤°ê«e°}¤lµo¥¬´f¥x31¶µ¬Fµ¦ >>ÂE®ü¶°¹ÎªºFII¥ú³tµn¤WAªÑ...

´ä¥æ©Ò¶}¤jªù¦V¥xÆW¥Í§Þ·~©Û¤â >>¥xÆW¥Íµ¦·|¦Ü­»´ä°Ñ¥[2018­»´ä¥Íª«¬ì§Þ®p·|...

¥Íµ¦·|¦^¥x«Å¥¬..²Ä¤@½ü³W¹º±ÀÂË2®a¥Í§Þ¤½¥q­u´ä±¾µP

¤¤°ê³Ìªñªº¬Fµ¦¬O³s³eªº...¤£­n¥h±Æ¥¸¥ô¦óªº¾÷·|...

¥Í§Þ·sÃĤ½¥q¦Ü­»´ä±¾µP...Àò¨ú§ó¦h¸êª÷¹ï·sÃĤ½¥q¥[³tÁ{§É±À¦æ¦³«Ü¤jªºÀ°§U...

·sÃĶV¦­¦¨¥\¤W¥«...À°§Uªº¬O¥@¬É¤WµL¼Æªº¯f¤H...

4/2¤é³ø¾É¥Íµ¦·|¦¹¦æ¥h­»´ä¦^¥xªºµ²ªG...¤ß®®ªºªÑªF·|·í¤é°¨¤W§ó§ï®É¶¡...«Ü¥©§a

·|­û:²q·Q10136148µoªí®É¶¡:2018/4/3 ¤W¤È 08:04:31²Ä793½g¦^À³
¤ß®®¤S§âªÑªF·|¤é´Á§ï¦^©¹±`ªº¤ë©³¥l¶}

¨Ì¨S´£¼W¸ê¨Æ¶µ?

¤½§i¥»¤½¥q¸³¨Æ·|¨MijÅܧó¥l¶}107¦~ªÑªF·|¬ÛÃö¨Æ©y

1.¸³¨Æ·|¨Mij¤é´Á:107/04/02

2.ªÑªF·|¥l¶}¤é´Á:107/06/28

3.ªÑªF·|¥l¶}¦aÂI:·s¥_¥«¦Á¤î°Ï·s¥x¤­¸ô¤@¬q97¸¹4¼Ó

(B´É»·¶¯U-Town±µ«Ý¤¤¤ß¡^

4.¥l¶°¨Æ¥Ñ:

¤@¡B³ø§i¨Æ¶µ

(¤@)¤@¡³¤»¦~«×Àç·~³ø§i

(¤G)¤@¡³¤»¦~«×¼f­p©e­û·|¬d®Ö³ø§i

(¤T)¤@¡³¤»¦~«×°·¥þÀç¹B­pµe³ø§i

¤G¡B©Ó»{¨Æ¶µ

(¤@)¤@¡³¤»¦~«×Àç·~³ø§i®Ñ¤Î°]°È³øªí®×

(¤G)¤@¡³¤»¦~«×Á«·l¼·¸É®×

¤T¡B°Q½×º[¿ïÁ|¨Æ¶µ

(¤@)¸É¿ï¿W¥ß¸³¨Æ®×

(¤G)¸Ñ°£¸³¨ÆÄv·~­­¨î®×

5.°±¤î¹L¤á°_©l¤é´Á:107/04/30

6.°±¤î¹L¤áºI¤î¤é´Á:107/06/28

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

­q©ó107¦~04¤ë20¤é°_¦Ü107¦~04¤ë30¤é17®É¤î¨ü²zªÑªF´£®×º[¿W¥ß¸³¨Æ´£¦W¡C

·|­û:³¯ÀR10141886µoªí®É¶¡:2018/4/3 ¤W¤È 03:09:22²Ä792½g¦^À³
¥Íµ¦·|§j¤û¡C´ä¥æ©Ò¼f¬d©M¥Íµ¦·|¨SÃö«Y¡C§O§Ñ¤F­»´ä¬O¤¤°ê»â¤g¡A«ç·|Å¥¥xÆW»¡¤T¹D¥|¡C´ä¥æ©Ò¼f¬dÄY®æ¡A¥xÆW¤½¥q¦³¤½¥­Ävª§¾÷·|´N«Ü¤£¿ù¡A¤£­n·Q«O°e¤F¡CºØ»G­n§j¤û¥xÆW¥Í§Þ¦p¦ó¦p¦ó¡B©Ô´ä¥æ©Òªº¸ÈÂ\¦³¥Î°¨¡H¤ß®®¦p¦óµo®i¡A»õ´úµL¥Î¡Bµ¥µÛ¬Ý¤~¹ï¡C
·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/4/3 ¤W¤È 12:38:21²Ä791½g¦^À³
¤À¨É4/2¤é³Ì·s¥Í§Þ­u´ä±¾µP³ø¾É°T®§...­«ÂI¦p¤U:

---------------------------------------------------------------------------------------------------

1.¤ß®®²Å¦X­u´ä±¾µP¸ê®æ

2.¥xÆW¥Íµ¦·|²Ä¤@½ü³W¹º±ÀÂË2®a¥Í§Þ¤½¥q­u´ä±¾µP

----------------------------------------------------------------------------------------------------

2018¦~04¤ë02¤é 04:10 ¤u°Ó®É³ø §ù¿·»T¡þ¥x¥_³ø¾É

´ä¥æ©Ò¶}¤jªù¦V¥xÆW¥Í§Þ·~©Û¤â¡A§Æ±æ³z¹L¡u¥«³õ´«§Þ³N¡v±a°Ê³Ð·s²£·~µo®i¡I¾Ú¤F¸Ñ¡A

´ä¥æ©ÒÀÀ©ó10¤ë¤½§i¡A»{ÃÒ¥xÆWTFDAªº¤G´ÁÁ{§É·sÃÄ¡B¼fij©e­û·|±N¯Ç¤J¥xÆW±M®aµ¥¹ªÀy¬Fµ¦¡A

§l¤Þ¨ã¼ç¤Oªº¥xÆW¥Í§Þ·~«e©¹­»´ä³Ð·~ª©±¾µP¡C

¡½³Ð§ë­I´º¶¯«pªº³ß±d³Ì¬Ý¦n

¨Ì¥Ø«eªº¬Fµ¦¤è¦V¡A¥]¬A³Ð§ë­I´º¶¯«pªº³ß±d³Ì¤W¬Û¡A¦Ó¥«¬ù¹F15»õ´ä¤¸¡]55»õ¥x¹ô¡^ªùÂeªº

ªk¼wÃÄ¡BÁp¥ÍÃÄ¡B¬u²±¡B¤ß®®©M¥xÂå¤]³Æ¨üÃöª`¡C¦¹¥~¡A¥]¬AÑÔ¼wºX¤UªºªFÂ`¡B¤w¨ú±o¤é¥»ÃÄÃÒªº®õ¦X¡A

«h§Æ±æ¦A¸g¹L¨â½ü¶Ò¸ê¡AÅýªÑªF¦¨¤À©M°ê»Ú¦X§@®×¦³©ú½T¶i«×«á¡A¦A«e¶iIPO¡C

¦Ü©ó¥ý«e¦b¥x¤W¥«®×¨üªýªº¥¿Ãv¡B¤WÂdºM¥óªºÂ׵ءA¥¼¨Ó¬O§_·|¦]·~ÁZ¦¨ªø©M®ü¥~­q³æÀu¶Õ«e¶i±¾µP¡A

«h¦³«ÝÆ[¹î¡C

¡½¹ªÀy±¹¬I¥i±æ10¤ë¤½¥¬

¥Íµ¦·|ªí¥Ü¡A¥Í§Þ²£·~¥D¬yÁͶդw©w¡A­»´ä¬°¾d©T¨ä¨È¬wª÷¿Ä»P¸ê¥»¥«³õ¦a¦ì¡A

¿n·¥¹ªÀy¹Ò¥~¥Í§ÞÂåÀø¥ø·~­u´ä¤W¥«¡A±N­×§ï¨S¦³À禬Àò§Qªº³Ð·s¤½¥q¡B¡u¦PªÑ¤£¦PÅv¡vµ¥¤W¥«³W«h¡A

¹w­p4¤ë©³±N¤½¥¬¹ê¬I²Ó¸`¡F¥t¥~¡A­ì¥»¥u»{ÃÒ¼Ú¡B¬ü¡B¤j³°ªºÁ{§É¹êÅç¡A

¥Ø«e¤]³W¹º»{ÃÒ¥xÆWTFDAªº¤G´ÁÁ{§É¡A¥B12¦ì¼fij©e­û·|¤]±N¯Ç¤J1-2¦ì¥xÆW±M®a¡A

¸Ó­×¥¿ªº±ø¤å¥i±æ¦b10¤ë¶¡¤½¥¬¡C

¡½¥Íµ¦·|±ÀÂË3®a­u´ä±¾µP

¦b²Ä¤@½ü³W¹º¦b­»´ä³Ð·~ª©±¾µPªº¤½¥q¤¤¡A¤j³°±N¥ÑÃÄ«P·|¡A¥xÆW«h¥Ñ¥Íµ¦·|¤À§O±ÀÂË3®a¡B

2®a¥Í§Þ¤½¥q¡AÁ`­p¬ù¦³11®a¤½¥q¶}±Ò¥ý¨Ò¡C

¥Íµ¦·|ªí¥Ü¡A¤é«e°Ñ¥[¡u2018­»´ä¥Íª«¬ì§Þ®p·|¡v¡A¨Ã«ô·|­»´ä«e¯S­º±ç®¶­^¡C¥Íµ¦·|¤Þ­z±ç®¶­^ªº¸Üªí¥Ü¡A­»´äµ²¦X¿Dªù¡B²`¦`¡B¯]®üµ¥¥H¼sªF¸Ü¬°¤H¤fªº¦a°Ï§Y¦³7¤d¸U¤H¡AGDP²£­È¤W1¥ü¦h¬ü¤¸¡A¤w¬Û·í©óÁú°êªº³W¼Ò¡C

¬°¤F¹ªÀy³Ð·s¥ø·~¤]¯à«e¶i­»´ä§ë¸ê¡A­»´ä§ó²½¥X³Ð·s¤½¥q¦b­»´ä¬ãµo¨Ã¶¶§Q¨ú±o¤W¥«³\¥i¡Aµ¥©ó¬OÅý´ä¡B¿D¡B¸f¼s¤j°Ï°ìªºÂå°|¥þ­±±Ä¥Îªº¤û¦×¬Fµ¦¡A¥B³Ð·s¤½¥qÁÙ¥i¶i¤J¸ê¥»¥«³õÄw¸ê¡C¨¬¨£­»´ä¬O¥H¡u¥«³õ´«§Þ³N¡vªºµ¦²¤¡A¦V°ê»Ú³Ð·s¤½¥q©Û¤â¡C

µØ«Â³Ð§ë¦X¹Ù¤H§õ¥@¤¯ªí¥Ü¡A´ä¥æ©Ò­º³Ð³Ð·~ª©ªºIPO³W¹º¡A¬O¤ñ·Ó¬ü°ê¼Ð·Ç¡A¥Ñ«ß®v¨Æ°È©Ò°e¥ó¡A¨é°Ó¶i¦æ©Ó¾P¡F¬°¤F¬ðÅã®æ§½¡AIPO¤½¥q¥²¶·­n¦³¨ã°ê»Ú±M·~­I´ºªº¥~³¡ªÑªF¡A¦pªG¡u°ê»Ú¬G¨Æ¡v³sµ²¤£±j¡A®£Ãø²æ¿o¦Ó¥X¡C

(¤u°Ó®É³ø)

°Ñ¦Ò³ø¾É¨Ó·½ºô§} www.chinatimes.com/newspapers/20180402000198-260202

·|­û:¤p·ç10140606µoªí®É¶¡:2018/4/2 ¤U¤È 10:42:13²Ä790½g¦^À³
¤p©¯¹B¤j±z¦n,

ÁÂÁ±z¤À¨É¦³Ãö¶i¤áªº¬Fµ¦¡A

¤£¹L§Ú­Ó¤H¤ñ¸ûı±o¶i¤á§ß«ù¥Í§Þªº¬Fµ¦¬O¦b¥´°²²y¡A

Á¿¨Ç¦nÅ¥¸Ü½}¤F¡A

¨ä¹ê§Ú­ÌÆ[¹î¥Ø«e©Ò¿×ªº©ñ¼e±ø¥ó¡A

³£ÁÙ¬O¤@¼Ë­n¨D­n¦³À禬¡A¨ä¹ê®Ú¥»¬O¬°¹q°Ó©M»s³y·~¶q¨­¥´³yªº¡A

¥úÀ禬³oÂI´N°ô¦í¤F©Ò¦³·sÃļt°Ó¡A

ÂûÀn©M¯E­ô¸Ñª¼¤£§Q¡A¤w¸gÅý¶i¤áÅK¤F¤ß¡A´N¬O§â·sÃĤ½¥q·í¶BÄF¶°¹Î¡A

¥¼¨Ó¨SÀ禬ªº·sÃÄ­n¯à¹³¯E­ô©Î¸Î§Ì¤@¼Ë¤WÂdªº¥i¯à©Ê·L¥G¨ä·L¡A

¥t¥~¶i¤á¦³Ãö³Ð§ëªº³W©w©ñ¼e¡A¨ä¹ê¤]¤£¬O¬°¤F¥Í§Þ¡A

¦]¬°°ê¤º³Ð§ë´±§ë¥Í§Þªº¤]¨S´X®a¡A´Nºâ´±§ëªº¡A¤]¬O¿³Âd°¨¤W¥X²M¡A

¤j®aÁÙ¬O´Á«Ý¨ì­»´ä¤ñ¸û¹ê»Ú~

¥H¤W­Ó¤H²L¨£~

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/3/31 ¤W¤È 10:48:23²Ä789½g¦^À³
¬F©²¤O®¼¥Í§Þ..¬Fµ¦³°Äò±À¥X...¸êª÷±N¥[³t´é¤J...

»P¸êª÷¦³Ãöªº³¡¤À.Â^¨ú­«ÂI¦p¤U:

--------------------------------------------------------------------------------------------------

ÅU¥ß¶¯ªí¥Ü¡Aª÷ºÞ·|±À°Êª÷¿Ä·~¨ó§U¥ÍÂå·~ªº±¹¬I·¥¦h¡A

¦p©ñ¼e»È¦æ¤Îª÷±±ºX¤U³Ð§ë¨Æ·~¡A¤]¶}©ñ§ë«H¨Æ·~±o¥Ó½ÐÂà§ë¸ê¤l¤½¥q¾á¥ô´¶³q¦X¹Ù¤H¡]General Partner¡^

¡A»P¥X¸êªÌ¡]Limited Partner¡^¦@¦P³]¥ß¨p¶ÒªÑÅv°òª÷¡]PE Fund¡^Âà§ë¸ê¥ÍÂå²£·~

---------------------------------------------------------------------------------------------------

2018¦~03¤ë31¤é 04:10 ¤u°Ó®É³ø ÃQ³ì©É¡þ¥x¥_³ø¾É

­»´ä²½¥X·sªk§l¤Þ¥ÍÂ夽¥q­u´ä±¾µP¡Aª÷ºÞ·|¥D©eÅU¥ß¶¯¬Q¡]30¡^¤é±µ¨ü¥»³ø±M³X®É«ü¥X¡A²{¦b¦U°ê¸ê¥»¥«³õ³£¦b©é¡A¡u¥xÆW¦³§Ú­Ìªº¬Û¹ïÀu¶Õ¡C¡v´N¥Í§Þ²£·~¨Ó¬Ý¡A­»´äªºÀu´f¥D­n¬O°w¹ï¤j³°¥ø·~¡A¥xÆWÀu¶Õ¦b©ó¡u¥Í§Þ²£·~»E¸¨¦¨«¬¡v¡B¡u¥ÍÂåªÑ¤W¥«Âd±ø¥ó¡v§ó¼eÃP¡A¥h¦~10¤ë¥H¨Ó¡A¤W¥«¤w¦³10®a¡B¤WÂd9®a¡C

¬°¤F®¼¥xÆW¥Í§Þ²£·~¡AÅU¥ß¶¯«ü¥X¡Aª÷ºÞ·|¥h¦~­º«×°Ñ¥[¥Í§Þ²£·~µ¦²¤¿Ô¸ß©e­û·|ijBTC¡A¨Ã¹ï·~ªÌªº¤C¤j°ÝÃD´£¥X¹ïµ¦¡C¥]¬A¡G¶}©ñ«OÀI·~ªÌ°Ñ»P»·¶ZÂåÀø¬ÛÃö¨Æ·~¡B³Ð³y¤Íµ½§ë¸êÀô¹ÒÁקK¹L«×ºÞ¨î¡B¥[±j»P·~¬É·¾³qÃP¸j¤£¦X²zºÞ¨î¡B¹ªÀy¥ÍÂå·~¤W¥«Âd«ì´_IPO/SPOºa´º¡B­û¤u¬ÛÃö¼ú¹S¶}©ñµ¹«D¥þ¾¤§ÅU°Ý¡B¤W¥«Âd«D¥HÀò§Qµû¦ô¬°¥D­n¼f¬d¼Ð·Ç¡A¥H¤Î§ïµ½¤u·~§½¤ÎÂd¶R¤¤¤ß²{¦æ¼f¬d¾÷¨îµ¥¡C

ÅU¥ß¶¯«ü¥X¡A¥Í§ÞÂåÀø¦b¥xÆW¸ê¥»¥«³õ¤w§Î¦¨²£·~Ãìµ²¤Î»E¸¨¡A¥Í§ÞÂåÀøÃþªÑ¤w¦³32®a¤W¥«¡B81®a¤WÂd¡B59®a¿³Âd¡C

¾ÚÂd¶R¤¤¤ß²Î­p¡A¥Í§ÞÂåÀøªÑ³Ìªñ¤T¦~¥Ó½ÐIPO®a¼Æ±Æ²Ä¤@¡A¦Ó¥Í§Þ¤½¥q¥Ó½Ð¤WÂd¼fij³q¹L¤ñ²v¤]¹F87¢H¡B¥Í§Þ¥BÄݬì§Þ¨Æ·~³q¹L²v¹F85¢H¡C¤WÂd¥Í§ÞÂåÀøÃþªÑ®a¼Æ³v¦~¦¨ªø¡C

¦b¥Í§Þ¤½¥q¥Ó½Ð¤WÂd±¾µP±ø¥ó¨Ó¬Ý¡A¥xÆW¤£¥u¤ñ­»´ä¼eÃP¡A´N¬O¦b¥þ²y¤]¦³Ävª§¤O¡C´N¥«­È³¡¥÷¡A­»´ä­n¨D¥«­È¦Ü¤Ö15»õ´ä¹ô¡A¥xÆW¨S¦³­n¨D¡C¦Ó¦b¬ãµo¶i«×¤Wªº­n¨D¡A­»´ä­n¨D¦Ü¤Ö­n¦³¤@­Ó²£«~¨ú±o²Ä¤G¶¥¬q´ú¸Õ¡A¥xÆW¤]¨S¦³­n¨D¡A¥t¥~¡A­»´ä¹ïªø´Á§ë¸êªÌ¤]¦³­n¨D¡A¥xÆW¤]¨S­n¨D¡C

ÅU¥ß¶¯»{¬°¡A­»´ä³o¦¸¥D­n¬O§l¤Þ¦³¤@©w³W¼Òªº¥Í§ÞÁÙ¦³ºô³q¬ì§Þ¤½¥q¡A»P¥xÆW·Q§l¤Þªº¨ú¦V¤£¤@¼Ë¡A¥xÆW¦³¦Û¤vªºÄvª§Àu¶Õ¡C

ÅU¥ß¶¯ªí¥Ü¡Aª÷ºÞ·|±À°Êª÷¿Ä·~¨ó§U¥ÍÂå·~ªº±¹¬I·¥¦h¡A¦p©ñ¼e»È¦æ¤Îª÷±±ºX¤U³Ð§ë¨Æ·~¡A¤]¶}©ñ§ë«H¨Æ·~±o¥Ó½ÐÂà§ë¸ê¤l¤½¥q¾á¥ô´¶³q¦X¹Ù¤H¡]General Partner¡^¡A»P¥X¸êªÌ¡]Limited Partner¡^¦@¦P³]¥ß¨p¶ÒªÑÅv°òª÷¡]PE Fund¡^Âà§ë¸ê¥ÍÂå²£·~¡A¡u¯à¶}³£¶}¤F¡v¡C

¹ï©ó¥Í§Þ·~ªÌ¤@ª½»{¬°¥xÆW¤W¥«Âd¦³¡u¼ç³W«h¡v¡AÅU¥ß¶¯»{¬°¡AÂd¶R¤¤¤ß¤´¶·ÅU¤Î±¾µP¤½¥qÀç¹B°·¥þ¼f¬d¡A±q·s³Ð²£·~¨ì¿³Âd¡B¤WÂd¡A°]³ø¡B¤½¥qªv²z³£ÁÙ¬O­n¦³¤@©w¤ô¥­¡C

(¤u°Ó®É³ø)

°Ñ¦Ò¨Ó·½ºô§}www.chinatimes.com/newspapers/20180331000189-260202

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/30 ¤U¤È 04:24:05²Ä788½g¦^À³
½LÂIÂù¬Û±¡·P»ÙêÁ{§ÉÃĪ«TOP10

¨Ó·½¡G ¦Ì¤ººô ¡@§@ªÌ¡G½²¼w¤s¡@2018-03-30

med.sina.com/article_detail_103_1_43587.html

Âù¬Û±¡·P»Ùê¡]BPS¡^¥çºÙļÆ{¯g¡C°ê¤º¥~¤£¤Ö¬Fªv¡B¤å¤Æ¦W¤H¦p¥C¦Nº¸¡BªLªÖ¡B±ë°ª¡B®ü©ú«Â¡Bº¿ÄR½¬¹ÚÅSµ¥§¡±w¦³¦¹¯f¡CBPS¬O¤@²Õ¯«¸g¨t²Îµê®z¦ÓµL¾¹½è©Ê·l®`ªº¥\¯à©Ê¯gª¬¡A¨ä¥D­nªí²{¬O±¡ºü¯gª¬¡B¦Ù¦×ºò±i©Ê¯kµh¤ÎºÎ¯v»Ùê¡A¨ã¦³°ª½Æµo²v¡B°ª»~¶E²v¡B§CªvÀø²vªº¤T¤j¯SÂI¡C«C¤Ö¦~¦p±w¦¹¯f¡A¦b¦¨ªø´Á«Ü®e©ö©¿µø¡A¦¹¯f¦b¦Ñ¦~¸sÅ餤¤]¦³µo¥Í¡C

BPS¬°ºë¯«¥¢½Õ¾É­Pªº¶¡Â_©Ê¤ß¹Ò¡Aºë¤O©M¥\¯à¹B§@«D¥¿±`ÅܤơAµo§@®É±¡ºüªi°Ê¸û¤j¡A¬O¬J¦³Ä¼¨g­Ý¦³§íÆ{ªºÅãµÛ¯S¼xªº¤@ºØ²×¨­¯e¯f¡C¯e¯f¦b½á¤©¤H­ÌÀu¶V»P§Ö¼Öªº¦P®É¡A±a¨Ó¯Ü®zªº¦ÓµLªk§Ô¨üªº§x­W¡A¬Æ¦Ü¾É­P¦Û±þ°Ê¾÷©M¦æ¬°¡C

WHO¼Æ¾ÚÅã¥Ü¡A¥þ²yBPSªºµo¯f²v¬°1%¡ã3%¡A³¡¤À°ê®a¥i°ª¹F5%¡ã7%¡AÁ`¦@¦³6000¸U¤H¨ü¨ì¸Ó¯e¯fªº§é¿i¡C²Î­p¼Æ¾ÚÅã¥Ü¡A2016¦~¥þ²y500±jÃÄ«~¥«³õ¤¤¡Aºë¯«©M¯«¸gÃþªvÀøÃĪ«¤w¹F¨ì784.22»õ¬ü¤¸¡A¦ûÁ`Å饫³õªº15.70%¡A¦P¤ñ¤W¤@¦~¼Wªø¤F12.67%¡C

WHO¼Æ¾ÚÅã¥Ü¡A¥þ²yBPSªºµo¯f²v¬°1%¡ã3%¡A³¡¤À°ê®a¥i°ª¹F5%¡ã7%¡AÁ`¦@¦³6000¸U¤H¨ü¨ì¸Ó¯e¯fªº§é¿i¡C²Î­p¼Æ¾ÚÅã¥Ü¡A2016¦~¥þ²y500±jÃÄ«~¥«³õ¤¤¡Aºë¯«©M¯«¸gÃþªvÀøÃĪ«¤w¹F¨ì784.22»õ¬ü¤¸¡A¦ûÁ`Å饫³õªº15.70%¡A¦P¤ñ¤W¤@¦~¼Wªø¤F12.67%¡C

¤¤°ê(¤j³°)½Ï¥Í¥@¬É­º¨Ò¯«¸g¯e¯f°ò¦]ºV¤J½Þ

¨Ó·½¡G ¤¤°ê«C¦~³ø ¡@§@ªÌ¡Gªô±á½÷¡@2018-03-30

med.sina.com/article_detail_103_1_43578.html

Ä~¥@¬É­º­ÓÅé²Ó­M§J¶©µU¤§«á¡A§Ú°ê¦b¤j°Êª«¼Ò«¬¬ã¨s»â°ì¤S½Ï¥Í¤@¶µ­«­n¦¨ªG¡X¡X¥@¬É­º¨Ò¯«¸g¯e¯f°ò¦]ºV¤J½Þ¦b¤¤°ê½Ï¥Í¡C

°OªÌ±q¤¤°ê¬ì¾Ç°|¼s¦{¥Íª«ÂåÃÄ»P°·±d¬ã¨s°|Àò±x¡A¥Ñ¤¤°ê¬ì¾Ç®a»â»Îªº°ê»Ú¬ã¨s¹Î¶¤¸g¹L4¦~§V¤O¡A§Q¥Î°ò¦]½s¿è§Þ³N©MÅé²Ó­M®Ö²¾´Ó§Þ³N¡A¦¨¥\°ö¨|¥X¥@¬É­º¨Ò¦ë§Ê¹y»RÁЯf°ò¦]ºV¤J½Þ¡Aºë·Ç¦a¼ÒÀÀ¥X¤HÃþ¯«¸g°h¦æ©Ê¯e​​¯f¡C

¸Ó¹Î¶¤ºÙ¡A¯«¸g¯e¯f°ò¦]ºV¤J½Þªº¦¨¥\±N±À°Ê§Ú°êµo®i¥X¤j°Êª«¯e¯f¼Ò«¬ªºÂåÃĬãµo²£·~Ãì¡A«P¶i°w¹ïªüº¸¯ý®üÀq¯f¡B©¬ª÷´Ë¯gµ¥¯«¸g°h¦æ©Ê¯e​​¯f¥H¤Î§K¬Ì¯Ê³´¡B¸~½F¡B¥NÁ©ʯe¯fªº·sÃĬãµo¶iµ{¡C

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/3/30 ¤U¤È 02:17:44²Ä787½g¦^À³
¥Ø«e¬F©²¬Fµ¦¤j¤Oµo®i¥Í§Þ²£·~..«áÄò¥«³õ¸êª÷±N³°Äò´é¤J...¤À¨É¬Fµ¦§@¦h¸ê°T..¦p¤U¤å~~

----------------------------------------------------------------------------------

MoneyDJ ·s»D 2018-03-29 10:00:11 °OªÌ·s»D¤¤¤ß ³ø¾É

¥Í§Þ¤¤¤ß¤T½b»ôµo ¥Ø¼Ð¥´³y¥xÆW¦¨¨È¤Ó¥ÍÂå¬ãµo­«Âí

°]¹Îªk¤H¥Íª«§Þ³N¶}µo¤¤¤ß(¥H¤U²ºÙ¥Í§Þ¤¤¤ß)¶i¾n°ê®a¥Í§Þ¶é°Ï¤T½b»ôµo¡F¥Í§Þ¤¤¤ßªí¥Ü¡A¤µ(2018)¦~4¤ë¥þ­±¶i¾n°ê®a¥Í§Þ¶é°Ï«á¡A±N¥H¥´³y¥Í§Þ²£·~»E¸¨¡B±À°ÊÃÄ«~°Ó«~¤Æ¡B¸¨¹ê¥Í§Þ³Ð·s¨|¦¨µ¥¤T½b»ôµo¤è¦¡¡A¥´³y¥xÆW¦¨¬°¨È¤Ó¥ÍÂå¬ãµo²£·~­«Âí¡A¥þ­±´£¤É¥Í§Þ²£·~»ù­È¡A¨Ã´Á«Ý2025¦~¥xÆW¶}µo¥X20¶µ·sÃÄ¡B40¶µ°ª­ÈÂå§÷©ó°ê»Ú¤W¥«¡A¦A³Ð¥xÆW¥t¤@¥þ·s¥ü¤¸²£·~¡C

¥Í§Þ¤¤¤ß°õ¦æªø§d©¾¾±«ü¥X¡A¥h(2017)¦~¥Í§Þ¤¤¤ßµL½×¦b¬ãµo§ÞÂà¡B¬[±µ°ê»Ú¡BÁp·ù±À°Ê¡B°Ó¾÷©Ý®i¦¨ªG§¡¬Û·íÂ׺ӡA¥h¦~§ÞÂत¬ü¥ÍÂå¬L©M¯ó§ÜÀù´Óª«·sÃÄ¡A¬°°ê¤º­º©v¦Û¤¤¬ã°|¬ã¨s¡A¥æ¥Ñ¥Í§Þ¤¤¤ß¬ãµo¥[­È¡A¦¨¥\±ÂÅv¥xÆW¥Í§Þ¤½¥q§ÜÀù´Óª«·sÃĪº¦¨¥\®×¨Ò¡C

¦b¬[±µ°ê»Ú¤W¡A¥Í§Þ¤¤¤ßªí¥Ü¡A¤Þ¶i°ê»ÚAI¤j¼tInSilico Medicine¡A¦³®ÄÀ³¥Î¨äAI¡A§ïµ½§ÜÀùÃĪ«¶}µo¬yµ{¡A¦¨¬°°ê¤ºµo®i´¼¼zÂåÀø¸g¨å¦X§@®×¨Ò¡A¦Ó°Ó¾÷©Ý®i³¡¥÷¡A´Óª«·sÃÄÁp·ù¸g¹L2017¦~Á|¿ì¦h³õ°ê»Ú¥«³õ¬ã°Q·|¡A¤Þ»â´Óª«·sÃĤ½¥q§Ö³tÃìµ²¨È¤Ó¥«³õ¡A¨Ã¦êÁp¥xÆW¤Î°ê»Ú´Óª«·sÃĤ½¥q²Õ¦¨GACPÁp·ù¡A¦@¦Pñ¸p°ê»Ú¦X§@·N¦V®Ñ¡A³þ©w¥xÆWµo®i´Óª«·sÃĬãµo°í¹ê°ò¦¡C

¥Í§Þ¤¤¤ß¥çªí¥Ü¡A¤µ(2018)¦~¹ï¥Í§Þ¤¤¤ß¬O¤@­Ó¹ñ·sªº¨½µ{¸O¡A±N±À¥X¤T¤ä½b¾ã¦X¥xÆW¥Í§Þ²£·~¸ê·½¡A¥´³y¥xÆW¦¨¬°¨È¤Ó¥ÍÂå¬ãµo²£·~­«Âí¡A¦Ó¬°©IÀ³¬F©²5+2³Ð·s²£·~¬Fµ¦±À¥Xªº¡u¥ÍÂå²£·~³Ð·s±À°Ê¤è®×¡v¡A·í¤¤¾ã¦X¥Í§Þ»E¸¨ªº­«­nµ¦²¤¡A§Y»EµJ¦ì©ó«n´äªº°ê®a¥Í§Þ¬ã¨s¶é°Ï¡C

¬°¦¹¡A¥Í§Þ¤¤¤ß¥X²Ä¤@¤ä½b§Y¥þ­±¶i¾n°ê®a¥Í§Þ¬ã¨s¶é°Ï¡C§d©¾¾±ªí¥Ü¡A¦Û¥h¦~10¤ë­ºªi¶i¾n°ê®a¥Í§Þ¬ã¨s¶é°Ï¡A²{¤w¶i¾n¹F200¤H¡A¤µ¦~4¤ë±N¹ï¥~¥¿¦¡«Å¥¬©ó°ê®a¥Í§Þ¬ã¨s¶é°Ï¥þ­±®i¶}Àç¹B¡A¦ô­p¬ù¥H350¦ì¦P¤¯©ó°ê®a¥Í§Þ¶é°ÏE´É°õ¦æ¬ì§Þ¬ãµo»P¹ï¥~ªA°È¡A¨Ã»P¤¤¬ã°|¡B½ÃºÖ³¡­¹Ãĸp¡B¬ì§Þ³¡°ê®a¹êÅç°Êª«¤¤¤ß¦ê±µ¡A§Î¦¨¥xÆW·sÃĬãµoªº¤d¤H¥Í§Þ²£·~»E¸¨¡C

¥Í§Þ¤¤¤ß«ü¥X¡A²Ä¤G¤ä½b±N¥HÃÄ«~°Ó«~¤Æ¤¤¤ß¤§¨¤¦â»P¥ô°È¡A¨Ã¥H·sÃIJ£·~Ãì²Ä¤G´Î¤§©w¦ì»P¯à¶q¡A¨ó§U°ê¤º·sÃĶ}µo¤½¥q¤Î·s³Ð¹Î¶¤¡A¥[³t¥Í§ÞÂåÃIJ£­È±À¤É¡C§d©¾¾±»{¬°¡A¦h¦~¨Ó¥Í§Þ¤¤¤ß¦b·sÃĬãµoªº§Þ³N¡B¼ç¤O®×·½ªºµo±¸¡B´¼°]¥¬§½»P§ÞÂà´C¦X§¡¤w²Ö­p¦¨¥\¸gÅç¨Ã°ö¾i¦h¦ì±M®×»²¾É¥Í§Þ²£·~¤H¤~¡A¥Í§Þ¤¤¤ß±N¥H¬F©²­«­n¹õ¹±¨¤¦â¦¨¬°¥xÆW¥Í§Þ²£·~»âÀY¦Ï«e´£¤U¡A¦³®Ä§Ö³t¹B§@ÃÄ«~°Ó«~¤Æ¤¤¤ß¡A´£¨ÑÃÄ«~°Ó«~¤Æ¤@¯¸¦¡ªA°È¡A¦êÁp·sÃĶ}µoºôµ¸¡A¬ð¯}Á{§É¸ÕÅç²~ÀV¡A¥[³tÃÄ«~¤W¥«¤Î³Ð³y°ªªþ¥[»ù­È²£­È¡C

¥Í§Þ¤¤¤ß¥ç«ü¥X¡A²Ä¤T¤ä½b¬°¸¨¹ê¥xÆW¥Í§Þ³Ð·s¨|¦¨¡A¤µ¦~°_±N¥¿¦¡±Ò°Ê¼Æ¦ì°·±d¥[³t¾¹­pµe¡AºX¤U«n´ä¥Í§Þ¨|¦¨¤¤¤ß´£¨Ñ¸ó°ì³Ð·s¾ã¦X«¬ªA°È¡AÃìµ²·s³Ð¤½¥q¡B§ë¸ê¤H¡B¥ø·~®a¾É®v¡B©PÃä¾ã¦XªA°Èµ¥¸ê·½¡A¥[³t¥xÆW¼Æ¦ì³Ð·s¤½¥q°ê»Ú¤Æ¡C§d©¾¾±ªí¥Ü¡A´Á«Ý¥¼¨ÓÂǼƦ찷±d¥[³t¾¹­pµe¡A¥´³y¥xÆW¥ÍÂå»â°ì³Ð·~¨|¦¨¥ÍºA¨t¡A¥H±À°Ê§Ú°ê¥ÍÂå²£·~³Ð·sÂ૬¡A¦¨¥\»P°ê»Ú¥Í§Þ·s³Ð¤½¥q±µ­y¡AÅý¥xÆW¦¨¬°¨È¤Ó¦a°Ï¥Í§Þ·s³Ð²£·~­«­n±À¤â¡C

§d©¾¾±»{¬°¡A¥Í§Þ¤¤¤ß¥¼¨Ó±N¥i³z¹L¥´³y¥xÆW¦¨¬°¨È¤Ó¥Í§Þ­«Âíªº¤T¤ä§Q½b¡A¦¨¬°¥xÆW¥Í§Þ²£·~³Ì­«­n¤Þ»â«ü¼Ð¡A¤Þ»â¥xÆW¥Í§Þ·sÃĦb²£·~»E¸¨¡B³Ð·s¨|¦¨¡BÃÄ«~°Ó«~¤Æªº°ò©³¤W¡A±N·sÃIJ£·~±À¦V¥t¤@­ÓÅq®p¡A³Ð³y¦b°ê»Ú·sÃÄ¥«³õ¤W§ó¦h¦¨¥\¨å½d¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/29 ¤U¤È 03:47:06²Ä786½g¦^À³
´Ó¤J°O¾Ðªk¡G©Î¬°ªüº¸¯ý®üÀq¯f±wªÌ´M¦^°O¾Ð

¨Ó·½¡G°·±d¬É ¡@2018-03-29

½sĶ¡G§õ·q·q

med.sina.com/article_detail_103_2_43509.html

¡§´Ó¤J°O¾Ðªk¡¨¦³®Ä´£°ª±wªÌ°O¾Ð¤O

¬ã¨s¤H­û©Û¶Ò10¦W´¿°Ñ¥[¹L¨ä¥L¸£³¡¬ã¨sªºÅöíw¯g±wªÌ¬°¹êÅç¹ï¶H¡]ÀY³¡¤w¸g´Ó¤J¹q·¥¡^¡A­n¨D¥L­Ì¥J²ÓÆ[¹î¤@±i²³æ¹Ï§Î¡]¦p¦â¶ô¡^¡A»P¦¹¦P®É¡A¥L­Ìªº¤j¸£¬¡°Ê·|³Q°O¿ý¡FµM«á¬ã¨s¤H­û²MªÅ«Ì¹õ¡A­n¨D¹êÅç¹ï¹³±q5­Ó¿ï¶µ¤¤¿ï¥X¥¿½T¹Ï§Î¡C¹êÅç¹ï¶H°Ñ»P°O¾Ð¥ô°È¤§®É¡A¨äÀY³¡´Ó¤Jªº¹q·¥¦P¨BºÊ´ú¨ä¤j¸£¬¡°Ê¡A¨Ã©óµy«á¤ÏõX¡C¬ã¨s¤H­ûµo²{¡A·í³Q°O¿ý¤Uªº°O¾Ð¦b¹êÅç¹ï¹³®ü°¨Åé¸Ì¦^©ñ®É¡A¹êÅç¹ï¶Hªº°O¾Ð¤O´£°ª37%¡C¡]®ü°¨Å鬰­t³d°O¾Ð§Î¦¨ªºÃöÁ丣°Ï¡A¤]¬O³Ì¥ý³Qªüº¸¯ý®üÀq¯f«I®`ªº°Ï°ì¤§¤@¡^¡C

º~´¶´Ë»{¬°³o¤@§Þ³Nµo®iªÅ¶¡«Ü¤j¡C¥L§Æ±æ¥¼¨Ó³o¤@§Þ³N¯àÀ°§U¾ãÅé°O¾Ð¶}©l°I°hªº±wªÌ°O¦í¬Y¨Ç¨ãÅé¨Æ¶µ¡A¦p®a®x¦í§}¡B®]½ú¼Ë»ªµ¥¡C³o¤@¨t²Î¥i°µ¦¨ºØ´ÓÅé´Ó¤J¤HÃþ¤j¸£¡A«ùÄò´£°ª±wªÌ½s½X¡BÀx¦s·s«H®§ªº¯à¤O¡C¦Ó³o¼Ë¤@­Ó¯à°÷«ùÄòŪ¨ú¡B¤ÀªR¡B¤ä«ù±wªÌ©T¦³°O¾Ð¥\¯àªº³¬Àô¨t²ÎÁÙ¦b¬ãµo¤¤¡C¨ì®É­Ô±wªÌ»Ý©w´Á´_¶E¥H½T«O¸Ó¨t²Î¥¿±`¹B§@¡C

¥¿¦pº~´¶´Ë±Ð±Â©Ò»¡¡A¸Ó¬ã¨s¦¨ªG·N¸q­«¤j¡A¬O¬ì¾Ç®a­º¦¸¦¨¥\ÃѧO±wªÌ¦ÛÅ鸣²Ó­M°O¾Ð¥N½X¡]¼Ò«¬¡^¨Ã¥Î¦¹¥N½X¨Ó®Ñ¼g¥H§ïµ½°O¾Ð¤O¡C¥¦¬O¬ì¾Ç®a¦bªvÀø¥¢¾Ð¤è­±ÁÚ¥Xªº²Ä¤@¨B¡A¤]¬O­«­n¤@¨B¡C

¤£¤Ö­^°ê¬ÛÃö»â°ì±M®a¤]¯É¯Éªí¥Ü¸Ó¬ã¨s¬°¤HÃþ¶i¤@¨B²z¸Ñ¡§°O¾Ð§Î¦¨¡¨´£¨Ñ¤F­«­n°ò¥Û¡A¤]¬°±´´Mªüº¸¯ý®üÀq¯fÀøªk´£¨Ñ¤F·s«ä¸ô¡C¦Ó³o¤@½ÆÂø§Þ³NÁÙ¤£°÷¦¨¼ô¡A»Ý­n§ó¦h¸êª÷¨Ó¤ä«ù«áÄò¥´¿i¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/29 ¤U¤È 12:31:11²Ä785½g¦^À³
¸É¥R:

Abide¤½¥q¶}µoªºABX-1772¬O¤@ºØ¦P®É¹v¦V³æ酰¥Ìªo¯×ªÕ酶(monoacylglycerol lipase, MGLL)©M¯×ªÕ»Ä酰Ói¤ô¸Ñ酶(fatty acid amide hydrolase, FAAH)ªº¤p¤À¤l§í»s¾¯¡CMGLL©MFAHH³q¹L¤£¦P«H¸¹³q¸ô³£¥i¥H¹ï¤º·½©Ê¤j³Â¯À(endocannabinoids)«H¸¹³q¸ô¶i¦æ½Õ¸`¡A¦Ó¤º·½©Ê¤j³Â¯À«H¸¹³q¸ô¹ï¯«¸g»¼½èªº¥­¿Å¦³­«­n¼vÅT¡CABX-1772¬O¤@ºØ¯à°÷¶i¤J¤¤¼Ï¯«¸g¨t²Îªº¤p¤À¤l§í»s¾¯¡C¦bÁ{§É«e¬ã¨s¤¤¥¦³Q¥Î©óªvÀøÅöíw(epilepsy)¡C

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/29 ¤U¤È 12:20:02²Ä784½g¦^À³
ÁÂÁ¤p©¯¹B¤j

Celgene¤S¶R¤F¨â¶µµo®i¤¤·sÃÄ

Celgene¹F¦¨¨â¶µ¬ãµo¨óijÂX®i¤½¥qÃĪ«¬ãµoºÞ½u

¨Ó·½¡GÃÄ©ú±d¼w¡@2018-03-29

med.sina.com/article_detail_103_2_43485.html

¤é«e¡A·s°ò(Celgene)¤½¥q«Å¥¬¤À§O»Pbluebird bio¤½¥q©MAbide Therapeutics¤½¥q¹F¦¨¦X§@¬ãµo¨óij¡A¶i¤@¨BÂX®i¤F¸Ó¤½¥qªºÃĪ«¬ãµoºÞ½u¡C

1.

bb2121¡GÅåÆvªº©ú¬PÀøªk

2017¦~6¤ë¡A¦bASCO¦~·|¤W¡AÂų¾¾ÌÂÇbb2121¤@»ïÅå¤H¡A·|¤WÅåÆvªºÀø®Ä¼Æ¾ÚÅý¤j®a¹Ä¬°Æ[¤î¡A«ÈÆ[½w¸Ñ²v³ºµM¹F¨ì100%¡Cbb2121¬O¤@ºØ¹v¦VB²Ó­M¦¨¼ô§Ü­ì(BCMA)ªº¹êÅç©ÊCAR-TÀøªk¡C¨äªvÀø´_µo©Ê©MÃøªv©Ê(R/R)¦hµo©Ê°©Åè½F(MM)¤wÀò±oFDAªº¬ð¯}©ÊÃĪ«¸ê®æ(BTD)¡AªvÀøR/R MM¤]¤wÀò±oEMA±Â¤©ªºÀu¥ýÃĪ«¸ê®æ(PRIME)¡C

2.

»PAbide Therapeutics¤½¥qªº¦X§@¨óij«hÅý·s°ò¤½¥qÀò±o¤F¶i¤@¨B¶}µoAbide Therapeutics¤½¥q¶}µoªºÁ{§É«eÃĪ«ABX-1772ªº¥þ²y¿W®a±ÂÅv¡C

Abide¤½¥q¶}µoªºABX-1772¬O¤@ºØ¦P®É¹v¦V³æ酰¥Ìªo¯×ªÕ酶(monoacylglycerol lipase, MGLL)©M¯×ªÕ»Ä酰Ói¤ô¸Ñ酶(fatty acid amide hydrolase, FAAH)ªº¤p¤À¤l§í»s¾¯¡CMGLL©MFAHH³q¹L¤£¦P«H¸¹³q¸ô³£¥i¥H¹ï¤º·½©Ê¤j³Â¯À(endocannabinoids)«H¸¹³q¸ô¶i¦æ½Õ¸`¡A¦Ó¤º·½©Ê¤j³Â¯À«H¸¹³q¸ô¹ï¯«¸g»¼½èªº¥­¿Å¦³­«­n¼vÅT¡C

Abide received an undisclosed payment and will be entitled to certain milestone payments and royalties on commercial sales.

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/3/29 ¤W¤È 09:39:03²Ä783½g¦^À³
¥Í§Þ¤µ¦~¥D¬yÁͶճvº¥¥[·Å...

¤µ¤é¥Í§Þ«ü¼Æ¤w¤jº¦2%¥H¤W...¦A³Ð¾ú¥v·s°ª»ù¦ì...

¦p¥ý«e´£¨ì...¸êª÷·|³°Äò¦]°ê»ÚªÑ¥«¤£Ã­Ä~Äò´é¤J¥Í§Þ...

ÁͶզ污=¸êª÷+¤ß²z...

¤ß®®¬O¬°¥xÆW°ß¤@¬ü°êFDAµ¹¤©2±iBTD»{ÃÒªº°ª¼ç¤O·sÃĤ½¥q...

¸êª÷³°Äò´é¶i¥Í§Þ®É...¦ÛµM·|§l¤Þ§ó¦h±M·~§ë¸ê¤¤¹ê¤á¤Î¤j¤á¸êª÷...

¤¤ªø½u§ë¸êªÌ.¥i¶X¦­´£«e¥d¦ì...

¥t~~¤ß®®¥Ø«e©ó104¤H¤Oºô¤jÁ|¼x¤~¦@11­Ó¾¯Ê...

¥[¤W²q·Q¤j´£¨ì¤µ¦~ªÑªF·|´£«e¬ù1­Ó¤ë©Û¶}...ºØºØ¸ñ¶H..·¥¨ä¤£´M±`...

¥H¤W¸ê°T~~¨Ñ¦U¤¤ªø½u§ë¸êªÌ°Ñ¦Ò~~

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/3/28 ¤U¤È 10:56:25²Ä782½g¦^À³
²q·Q¤j~~~

¯u²Ó¤ß...©Î³\¦³Á{§É¼Æ¾Úªº¤½¥¬§a...´Nµ¥«ÝªÑªF·|§a!!

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/28 ¤W¤È 11:06:27²Ä781½g¦^À³
ªÑªF·|¥l¶}¤é´Á:107/06/01

¤µ¦~¤ß®®ªÑªF·|ªº¥l¶}¸û¤§«e¨â¦~´£¦­¬ù¤@­Ó¤ë

¦³¦ó¯S®í­ì¦]¶Ü?

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/26 ¤U¤È 08:06:04²Ä780½g¦^À³
¡uµL²K¥[¨¾»G¾¯¡v§ó¬r¡I¹A¾Ç³Õ¤hÃz¥«°â­¹«~ªº·t¶Â¯u¬Û

www.chinatimes.com/realtimenews/20180326003049-260418

¤é¥»¹A¾Ç³Õ¤h¦³¸ô©÷«Û´¦ÅS¥«°â­¹«~ªº·t¶Â¯u¬Û«ü¥X¡A¤£¨Ï¥Î¨¾»G¾¯¥i¯àÅý­¹ª«´þ¥Í²Óµß¡A¤Ï¦Ó¤ñ¨¾»G¾¯§ó¬r¡F¦¹¥~¡A¬°¤FÁקK·L¥Íª«¼W¥Í¡A¾¨ºÞ¼Ð¥Ü¡uµL²K¥[¨¾»G¾¯¡v¡A«o¥i¯à¨Ï¥Î¤F§ó¦h§A¬Ý¤£À´ªº¡u²K¥[ª«¡v¨Ó¥N´À¡I

®Ú¾ÚÁp¦X¤¸®ðºô³ø¾É¡A¦³¸ô©÷«Ûªí¥Ü¡Aªk³W¤W³Q¦CÁ|¬°¡u¨¾»G¾¯¡vªºª«½è¡A¥u­n¤Ö¶q¨Ï¥Î´N¦³¨}¦n®ÄªG¡A¦Ü©ó¨ä¥L²K¥[ª«¡A«h¥²¶·¨Ï¥Î¬Û¹ï¸û¦hªº¶q¤~¯à¹F¨ì®ÄªG¡C¦]¦¹¡A¤£¨Ï¥Î¨¾»G¾¯¦Ó§ï¥Î¨ä¥L²K¥[ª«¨Ó«O¦s­¹ª«¡A¬O¥»¥½­Ë¸mªº°µªk¡C¦Ó¥B¡u¨¾»G¾¯¡v¹ï¤HÅé°·±dªº¦M®`­·ÀI·¥§C¡A©Ò¥H°í«ù¡uµL²K¥[¨¾»G¾¯¡v¨ÃµL·N¸q¡C

·|­û:¤p¨È10135608µoªí®É¶¡:2018/3/26 ¤W¤È 10:14:37²Ä779½g¦^À³
¤p©¯¹B¤j¤j»¡±o¹ï·¥¤F¡A­Ó¤H«ùªÑ2®a¥Í§ÞªÑ¡A³£¬Oªø´ÁÆ[¹îº¦¶^¡A·m¦b¦UªÑIJ©³¥X¶q½´­®É§l¤j¤f®ð«i´±¶R¶i¡C

³o¦¸¤ß±o´N¬Oªi¬q©êµÛ¡A¶]¨Ó¶]¥h·|³Q¤£½T©w¦]¯À¬~¥X³õ¡A·Q¦A¶R¶i¥²¶·¦h¥I¤@¨Ç¦¨¥»¡A­n¾ß«K©y®£©È¤£®e©ö¡A³Ì©È¯Ê¥F«H¤ß¤U¤£¤F¤â¡A²´¸C¸C¬ÝµÛ¤@¸ô´­¤É¡A¦@«j¡C

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/3/26 ¤W¤È 09:52:05²Ä778½g¦^À³
¬üªÑ3/22-3/23 ¤j±þ2¤Ñ¦@¤U¶^1149ÂI...

¦ý¬Ý¤µ¤é¥xÆW¥Í§Þ«ü¼Æ...¥Ø«e¤jº¦2%¥H¤W...

¦p¥ý«e´£¨ì...°ê»Ú§½¶Õ¦]¬üªÑ°ÊÀú¤£¦w¤§»Ú...

¸êª÷·|³°Äò´é¤J¤w¶^¨â¦~ªº¥Í§Þ±Ú¸sÁ×ÀI...

--------------------------------------------------------------

«áÄò°ê»ÚªÑ¥«¶V¤£Ã­...¸êª÷´é¤J¥Í§Þ±Ú¸s·|§ó¥[³t...

¥[¤W¬F©²¬Fµ¦§@¦h¥Í§Þ...¤¤ªø½u§ë¸ê¤H¦n¦n§â´¤³o¦¸¤jªi¬q¦n¾÷·|...

¿ï¾ÜÀu½è·sÃĪѶi¦æ§ë¸ê...ÀHµÛ¸êª÷¤Î¬Fµ¦§@¦hªº¦æ±¡©ê¨c...

¥H¤W²L¨£~~¨Ñ¤¤ªø½uªø´Á§ë¸êªº¾Ô¤Í­Ì°Ñ¦Ò...

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/21 ¤U¤È 06:25:33²Ä777½g¦^À³
³Ì·s³ø§i¡Gªüº¸¯ý®üÀq¯fµo¯f²v¡B¦º¤`¤H¼Æ©MÅ@²z¶O¥Î«æ¼@¤W¤É

¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-03-21

med.sina.com/article_detail_103_2_43069.html

®Ú¾Ú³Ì·sªüº¸¯ý®üÀq¯f¨ó·|¤½§Gªº¡§2018¦~ªüº¸¯ý®üÀq¯f¨Æ¹ê©M¼Æ¦r¡¨³ø§i¡A³sÄò²Ä¤G¦~¡A¬ü°ê¥Î©óªvÀøªüº¸¯ý®üÀq¯g©Î¨ä¥Lè§b¯g±wªÌªºÁ`¤ä¥X¹w­p±N¶W¹L2500»õ¬ü¤¸(2770»õ¬ü¤¸)¡A³o¤ñ¥h¦~¼W¥[ªñ200»õ¬ü¤¸¡C

¨ä¤¤ÃD¬°¡§ªüº¸¯ý®üÀq¯f¡G¦­´Á¶EÂ_ªº¸gÀÙ©M­Ó¤HÀò¯q¡¨ªºÀHªþ¯S§O³ø§i¤¤ªº·s¸gÀÙ¼Ò«¬¼Æ¾Úªí©ú¡A¦b»´«×»{ª¾»Ù궥¬q¶i¦æ¦­´Áªüº¸¯ý®üÀq¯gªº¶EÂ_¡A¥i¥H¬°°ê®a¸`¬Ù°ª¹F¤C¸U¤E¤d»õ¬ü¤¸ªº°·±d©Mªø´ÁÅ@²z¶}¤ä¡C³ø§i±j½Õ¤F¦­´Á¶EÂ_¹ï­Ó¤H©M®a®xªº¦n³B¡C

ªüº¸¯ý®üÀq¯f³Ì·s²Î­p¼Æ¦r¡G

±w¯f²v¡Bµo¯f²v©M¦º¤`²v

.¾Ú¦ô­p¡A¦b2018¦~¡A±N¦³570¸U¦W¦U¦~ÄÖ¶¥¬qªº¬ü°ê¤H±w¦³ªüº¸¯ý®üÀq¯f¡C

.ªüº¸¯ý®üÀq¤ó¯g¬O¬ü°ê²Ä¤»¤j¦º¦]¡A¤]¬O65·³¤Î¥H¤W¤H¸sªº²Ä¤­¤j¦º¦]¡C

.ÀHµÛ¬ü°ê¤H¤fªº¦ÑÄ֤ơAªüº¸¯ý®üÀq¯g¥¿¦b¦¨¬°¤@ºØ§ó±`¨£ªº¦º¤`­ì¦]¡A¥¦¬O°ß¤@¤@­ÓµLªk¹w¨¾¡Bªv·U¬Æ¦Ü´î½wªº¤Q¤j¦º¦]¡C

ÂåÀø¶O¥Î

.2018¦~¡A¥þ°êªüº¸¯ý®üÀq¯g©M¨ä¥Lè§b¯g±wªÌªºÁ`Å@²z¶O¥Î¦ô­p¬°2770»õ¬ü¤¸¡]³o¤£¥]¬AµLÀv·Ó¬Ý¡^¡A¨ä¤¤1860»õ¬ü¤¸¬OÂåÀø«OÀI©MÂåÀø¸É§Uªº¶O¥Î¡F¦Û¶O¶O¥Î¦ûÁ`¥I´Úªº600»õ¬ü¤¸¡A¨ä¥L¶O¥ÎÁ`­p¤T¦Ê»õ¬ü¤¸¡C

.2050¦~¡Aªüº¸¯ý®üÀq¯g©M¨ä¥Lè§b¯g±wªÌªºÂåÀø¡Bªø´ÁÅ@²z©MÁ{²×ÃöÃhªºÁ`¤ä¥X¹w­p±N¶W¹L11000»õ¬ü¤¸(¥H2018¦~¬ü¤¸­p)¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/20 ¤U¤È 12:01:10²Ä776½g¦^À³
ÁÂÁ¤p©¯¹B¤j

Âűб³̪ñªº½×¤å

Acute Amino Acid D‑Serine Administration, Similar to Ketamine,Produces Antidepressant-like Effects through Identical Mechanisms

pubs.acs.org/doi/abs/10.1021/acs.jafc.7b04217?src=recsys&journalCode=jafcau

Acute Antidepressant Effects of D-Serine

¬O§_SNG-12ªºªvÀøªì´Á , ¥[¥Î°ª¾¯¶qªºD‑Serine , ¨Ó¥[±jSNG-12ªvÀøªì´Áªº§Ö³t§Ü§íÆ{®ÄªG???

·Q¤Ó¦h¤F!

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/3/20 ¤W¤È 10:28:05²Ä775½g¦^À³
²q·Q¤j~~

ÁÂÁ¤À¨ÉÄ_¶Q¸ê°T..SND-11/12/13­È±o´Á«Ý~~~

¤×¥HSND12/13¬ÒÀò±oBTD»{ÃÒ...µ¥«Ý¤µ¦~Á{§É¼Æ¾Ú¦³¦n¦¨ªG~~~

·|­û:²q·Q10136148µoªí®É¶¡:2018/3/19 ¤U¤È 05:02:48²Ä774½g¦^À³
The NMDA receptor ¡¥glycine modulatory site¡¦ in schizophrenia: d-serine, glycine, and beyond

www.sciencedirect.com/science/article/pii/S1471489214001714?via%3Dihub

Darrick T Balu (1,2) ;Joseph T Coyle (1,2)

1.Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA

2.Laboratory for Psychiatric and Molecular Neuroscience, McLean Hospital, Belmont, MA 02478, USA

Highlights

• NMDA receptor (NMDAR) hypofunction contributes to the etiology of schizophrenia.

• Serine racemase, a risk gene for schizophrenia, is expressed primarily in neurons.

• Knocking out serine racemase replicates many features of schizophrenia.

• Restoring d-serine levels reverses this schizophrenia-like neuropathology.

• «ì´_D-µ·®ò»Ä¤ô¥­¥i°fÂà³oºØºë¯«¤Àµõ¯g¼Ë¯«¸g¯f²z¾Ç¡C

• Enhancing NMDAR function may be an effective treatment strategy for schizophrenia.

• ¼W±jNMDAR¥\¯à¥i¯à¬Oºë¯«¤Àµõ¯gªº¦³®ÄªvÀøµ¦²¤¡C

SND-11 , 12 , 13 ­°§CDAAO¥NÁÂD-µ·®ò»Ä

SND-12 ¤S¦³´â´á¥­§U°},¦Ó´â´á¥­ªº§@¥Î¾÷¨î¥i¯àÁÙ¥]¬A¼W¥[D-µ·®ò»ÄªºÄÀ©ñ

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:¤ß®®¥ÍÂå
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!